| BioWorld

December - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Actelion Ltd. (Switzerland; SWX:ATLN)

Neopharm Ltd. (Israel)

Exclusive licensing agreement in which Neopharm will be responsible for the registration, marketing and reimbursement of Tracleer in Israel

Actelion Ltd. (Switzerland; SWX:ATLN)

Nova Factor Inc. (subsidiary of Accredo Health Inc.) and Gentiva Health Services

Distribution agreement for Tracleer

Albany Molecular Research Inc. (AMRI)

Pfizer Inc.

Three-year agreement in which AMRI will provide chemistry research, development and analytical services in a number of therapeutic areas; the contract includes fee-for-service provisions as well as opportunities for AMRI to receive success fees for early or cost-saving completion of projects

Alkermes Inc. (ALKS)

Reliant Pharmaceuticals LLC

$100

Reliant will market certain undisclosed Alkermes products, while Alkermes made a $100M equity investment in Reliant, acquiring about 19% of the company

Applied Molecular Evolution Inc. (AMEV)

Eli Lilly and Co.

Collaboration to optimize two of Lilly's protein therapeutics in return for an up-front signing fee, milestone payments and royalties on sales; Lilly retains the right to develop and commercialize products

Argenta Discovery Ltd. (UK)

GlaxoSmithKline plc (UK)

Research agreement to undertake a medicinal chemistry lead optimization program; Argenta will supply focused libraries and single compounds to GSK's drug discovery center based at the Stevenage Medicines Research Center in the UK

ArQule Inc. (ARQL)

Pfizer Inc.

$345

Extended and expanded agreement for ArQule's lead generation capabilities; ArQule will transfer its library design and informatics platform to Pfizer on a nonexclusive basis; Pfizer will make an initial $10M equity investment in ArQule and may increase that stake by another $8M, based on milestones; ArQule can expect potential payments ranging from $120M to $345M over the next seven years

Athersys Inc.

Pfizer Inc.

Multiyear drug discovery collaboration to provide cell lines expressing protein drug targets for undisclosed indications; Athersys will receive licensing fees for each validated target cell line it delivers, milestone payments, as well as royalty payments

BioFocus plc (UK; LSE:BIO)

GlaxoSmithKline plc (UK)

Research agreement for the development of new drug leads to treat asthma and chronic obstructive pulmonary disease; GSK will provide BioFocus with details of hit molecules identified from a screening program; BioFocus will optimize the molecules

Biora AB (Sweden; BIORY; SSE:BIOR)

Molnlycke Health Care AB (Sweden)

SEK10 (US$0.954)

Agreement for worldwide rights, excluding Japan, to Biora's development project in wound healing for chronic skin ulcers; Biora will receive a lump sum of US$953,781, as well as the right to milestone payments and royalty payments

Celera Genomics Group (NYSE:CRA)

Serono SA (Switzerland)

Agreement for a multiyear subscription to Celera's genomic databases; the mouse and human genome sequences will support Serono's drug discovery program

Cephalon Inc. (CEPH)

Sanofi-Synthelabo (France)

$32

Agreement to co-develop and co-market angiogenesis inhibitors for oncology in a deal worth up to $32M for Cephalon for the first product; the companies will jointly develop and market the inhibitors in the U.S., Canada and Mexico; the agreement focuses on CEP-7055; the deal includes an up-front license fee, milestone payments and royalties

CIMA Labs Inc. (CIMA)

Unnamed pharmaceutical company

A development, license and supply agreement for seven new undisclosed prescription products based upon CIMA's DuraSolv fast-dissolve drug delivery system; the agreement is expected to result in product development fees between $12M to $15M over the next three years; CIMA will be the exclusive manufacturer of these products and will receive royalties based on sales

Discovery Partners Internationl Inc. (DPII)

Pfizer Inc.

$95

Agreement to develop and produce libraries of high-purity chemical compounds to be used in Pfizer's drug discovery programs; the potential value of the four-year collaboration is $95M

Diversa Corp. (DVSA)

BASF (Germany)

Collaboration to evaluate selected biocatalysts and biological processes; any commercialized products will generate license revenues and royalties for Diversa

Entelos Inc.

Pfizer Inc.

Science and technology collaboration in which Pfizer will provide research funding and license fees to Entelos, as well as success fees and milestone payments; Entelos will prioritize specific Pfizer asthma drug candidates based on their predicted clinical efficacy using Entelos' Asthma PhysioLab technology

Evotec OAI AG (Germany; Neuer Markt:EVT)

Merck & Co. Inc.

Agreement to synthesize small-molecule chemical libraries; Evotec will synthesize drug-like library compounds and Merck will use the compounds in its drug research and development programs

Genaissance Pharmaceuticals Inc. (GNSC)

AstraZeneca plc (UK)

Agreement under which the companies will apply Genaissance's gene variation technology to one of AstraZeneca's target discovery programs; AstraZeneca will gain access to specific haplotypes and also use the DecoGen Informatics platform for correlating HAP markers to disease and/or clinical outcomes

Gene Logic Inc. (GLGC)

Aventis Pharmaceuticals Inc. (division of Aventis Pharma AG; Germany)

Genomics database agreement in which Aventis will establish a CustomSuite subscription, gaining access to a customized selection of biosamples from Gene Logic's GeneExpress Suite

Gene Logic Inc. (GLGC)

GlaxoSmithKline plc (UK)

Agreement in which GlaxoSmithKline adopted GeneLogic's GeneExpress suite of information products for use in its drug discovery and development efforts

Gene Logic Inc. (GLGC)

Pfizer Inc.

Expanded relationship in which Pfizer licensed Genesis the GeneExpress Enterprise System, Gene Logic's software and professional services for enterprise-wide data integration initiatives; the companies also entered into a predictive toxicology program agreement to generate a database related to the safety profile of compounds selected by Pfizer

Genzyme Corp. (GENZ)

Pharming Group NV (the Netherlands)

Agreement in which Genzyme will obtain all of Pharming's remaining assets related to the diagnosis and treatment of Pompe disease, including licenses to intellectual property and preclinical and clinical data

Guava Technologies Inc.

Bay Bioscience KK (Japan)

$5.5

A five-year distribution agreement for Bay to manage the distribution of the Guava Personal Cytometer in the Japanese market

Inhibitex Inc.

Nabi

Manufacturing agreement for 10 years for Inhibitex's lead product, INH-A21, at Nabi's Boca Raton facility

Interleukin Genetics Inc. (ILGN)

Kaiser Permanente's Center for Health Research

Research collaboration to study genetic risk factors for chronic diseases that are affected by inflammation

Isis Pharmaceuticals Inc. (ISIP)

Integrated DNA Technologies Inc.

$9.9

Antisense inhibitor supply agreement in which IDT will manufacture antisense inhibitors and research reagents; Isis will pay IDT $5M, and it also expanded its licensing agreement with IDT on certain patents; Isis will pay IDT $4.9M for the broadened IP license

ISTA Pharmaceuticals Inc. (ISTA)

Otsuka Pharmaceutical Co. Ltd. (unit of the Otsuka Group; Japan)

Agreements for Vitrase for the treatment of severe vitreous hemorrhage and diabetic retinopathy; Otsuka gained exclusive rights for the development and commercialization of Vitrase in Japan; ISTA will manufacture the product; Otsuka made an initial license fee payment and will make an additional payment when Vitrase is approved in Japan; Otsuka made a $4M equity investment in ISTA

MorphoSys AG (Germany; Neuer Markt:MOR)

Schering AG (Germany)

Collaboration for the development of antibody therapeutics and in vivo diagnostics; Schering will purchase a 10% equity stake in MorphoSys and MorphoSys will receive committed license fees and research and development funding over the three-year collaboration; the companies expect to pursue a minimum of five therapeutics and several in vivo diagnostics projects

Myriad Genetics Inc. (MYGN)

Laboratory Corporation of America Holdings

Partnership to make Myriad's predictive medicine products broadly available to primary care physicians throughout the U.S.; LabCorp gains exclusive sales and distribution rights to market Myriad's products

NeoPharm Inc. (NEOL)

Akorn Inc.

$3.25

Agreement to provide NeoPharm with the capacity to manufacture over 2M vials of cGMP material annually, beginning in 2003; NeoPharm will loan $3.25M to complete Akorn's lyophilization facility in Decatur, Ill.; in return for the loan, NeoPharm has the option to secure at least 15% of the manufacturing capacity for up to 15 years

Neose Technologies Inc. (NTEC)

Wyeth-Ayerst Laboratories (division of American Home Products Corp.)

$17

Research, development and license agreement for the use of Neose's GlycoAdvance technology to develop an improved production system for Wyeth's product, P-selectin glycoprotein ligand; Neose will develop processes for the commercial-scale manufacture of enzymes and sugar nucleotides used to produce rPSGL-lg

NeoTherapeutics Inc. (NEOT)

Pfizer Inc.

Agreement relating to the use of an orphan receptor identified by NeoGene, a NeoTherapeutics subsidiary; NeoTherapeutics will receive an initial payment and milestone payments

Neurogen Corp. (NRGN)

Aventis Pharma SA (Germany)

$10

Agreement to develop stress-related drugs; Neurogen receives a $10M initial payment, milestone payments and royalties; Aventis gains exclusive worldwide development, manufacturing, marketing and sales rights to compounds that come out of the collaboration

Oxford GlycoSciences plc (UK; OGSI)

Pfizer Inc.

Research agreement in which OGS will continue to apply its industrial scale proteomics technology to the discovery and utility of biomarkers in atherosclerosis, Alzheimer's disease and certain other undisclosed targets and indications

PhotoCure ASA (Norway; OSE:PHO)

Galderma SA (joint venture of L-Oreal and Nestle)

EUR30 (US$26.7)

Exclusive global licensing agreement for Metvix PDT, an approved treatment for cancerous and precancerous dermatological conditions; Galderma gains the exclusive right to market both the Metvix cream and Photocure's activating light sources outside the Nordic region; Photocure will receive EUR12M (US$10.7M) upon signing and an additional EUR18M (US$16M) as milestone payments

ProBioGen AG (Germany)

Merck & Co. Inc.

Exclusive research and license agreement to explore the development of cell substrates with potential application in the production of biologicals; the agreement includes an up-front payment, potential success-driven milestones and royalties from net sales

Proneuron Biotechnologies Inc.

Teva Pharmaceuticals Industries Ltd.

$10

Agreement to expand development of Copaxone; Proneuron will retain rights to develop it for spinal cord injury, amyotrophic lateral sclerosis and Huntington's disease; Teva gains rights to other neurological diseases such as Alzheimer's, stroke, brain trauma, glaucoma and Parkinson's; Proneuron will receive milestone payments and royalties; Teva made a $10M equity investment in Proneuron, and will fund all development and commercialization, as well as some preclinical research

Structural Bioinformatics Inc.

Boehringer Ingelheim Ltd. (Canada)

Research collaboration to use SBI's Variome database for Boehringer's in silico drug discovery of HIV protein targets; financial terms were not disclosed

Vical Inc. (VICL)

Aventis Pasteur SA (France)

Agreement giving Aventis rights to use Vical's gene delivery technologies for specific oncology applications; Aventis Pasteur is paying an undisclosed licensing fee and giving up its rights to develop and commercialize infectious disease vaccines and gene-based therapeutics for neurodegenerative diseases that were previously licensed from Vical

ViroPharma Inc. (VPHM)

Aventis Pharmaceuticals Inc. (division of Aventis Pharma AG; Germany)

Agreement in which the ViroPharma sales force will join Aventis to promote products from the Allegra family and Nasacort AQ to primary care physicians throughout the U.S. beginning next month; this agreement follows their agreement to jointly develop and promote Picovir in the U.S.

November - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Aclara BioSciences Inc. (ACLA)

Roche Applied Science (unit of Roche Diagnostics)

Collaboration for the worldwide marketing and distribution of Aclara's Arteas product line

Alteon Inc. (AMEX:ALT)

Chemi S.p.A. (Italy)

Manufacturing agreement in which Chemi will perform process validation, cGMP production of late-stage clinical batches and commercial manufacturing of Alteon's Advanced Glycosylation End-products crosslink breaker, ATL-711

Applied Gene Technologies Inc.

AsiaGen (Taiwan)

Manufacturing and marketing agreement to develop a product to combat the tuberculosis pandemic in China, India and the Pacific Rim; Applied Gene will receive an up-front payment, and will grant AsiaGen exclusive rights to market and manufacture the product in Asia

Arakis Ltd. (UK)

Penwest Pharmaceuticals Co.

Three-year alliance to develop up to six orally delivered performance-enhanced medicines for the treatment of pain conditions

Atugen AG (Germany)

Byk Gulden GmbH (Germany)

Evaluation agreement to investigate the efficiency and specificity of atugen's Gene-Bloc technology for the validation of novel cancer targets

Axxam S.r.l. (Italy)

Bayer AG (Germany)

EUR30 (US$26.5)

Collaboration in the field of post-genomics to develop several technology platforms for drug discovery; five-year research deal valued at US$26.5M, which involves Axxam developing a new generation of advanced assay systems to be used at Bayer's ultra-high-throughput screening unit for drug discovery

Cambridge Antibody Technology Group plc (UK; LSE:CAT)

Lonza Biologics Ltd. (Switzerland)

Long-term agreement for Lonza to manufacture and supply clinical-grade antibody drugs to CAT for up to five years

Celgene Corp. (CELG)

Pharmion Corp.

Licensing agreement for Thalomid (thalidomide); Pharmion gains international rights, excluding Canada, China, Japan, Taiwan and Korea; Celgene also has an option to acquire an equity stake in Pharmion; if exercised, it will receive royalties of 36 percent on Thalomid sales; otherwise, it will receive 10 percent

Celera Genomics Group (NYSE:CRA)

Otsuka Pharmaceutical Co. (Japan)

Multiyear subscription agreement for the Celera Discovery System; Otsuka will use Celera's database products, bioinformatics systems and other discovery tools in their research

Cellomics Inc.

Wyeth-Ayerst Laboratories (division of American Home Products Corp.)

Agreement to supply its ArrayScan HCS technology to the research unit of Wyeth-Ayerst Laboratories

CeNeS Pharmaceuticals Inc. (UK; LSE:CEN)

Scion Pharmaceuticals Inc.

$2.8

Agreement for Scion to acquire CeNeS' chemical libraries and associated intellectual property rights in the areas of sodium and calcium ion channels, as well as glutamate and sigma receptors; Scion will pay CeNeS $800,000 in staged payments and up to $2M in milestone payments

CeNeS Pharmaceuticals plc (UK; LSE:CEN)

Wyeth-Ayerst Research

Agreement granting Wyeth the use of CeNeS proprietary automated ion channel drug discovery technology; The system allows genuine electrophysical screening of ion channels at high throughput, potentially increasing the rate of the drug discovery process in ion channels

ChemNavigator Inc.

Alydar Pharmaceuticals Inc.

One-year cheminformatics services agreement in which ChemNavigator will perform cheminformatics analysis on Alydar's Pheromics library of infochemicals to help pinpoint their therapeutic potential

Chiron Corp. (CHIR)

Bristol-Myers Squibb Co.

Agreement for a nonexclusive license for the research, development and commercialization of small-molecule therapeutics against a broad spectrum of hepatitis C virus drug targets contained in the HCV genome

Dragon Pharmaceuticals Inc. (Canada; OTC BB:DRUG)

Emcure Pharmaceuticals Ltd. (India)

Marketing and license agreement for the distribution of Dragon's recombinant erythropoietin in India and throughout the South Asian subcontinent, as well as in markets in sub-Saharan Africa

Galapagos Genomics NV (Belgium)

Pharmacia Corp.

Functional genomics collaboration involving the use of Galapagos' PhenoSelect expression platform for gene target identification and validation applications; Galapagos will construct a gene library for Pharmacia to identify and validate drug targets in a broad range of disease areas

Genencor International Inc. (GCOR)

Procter & Gamble Co.

$600

Five-year worldwide supply contract to provide protease enzymes for laundry and dish detergents; the agreement is estimated to be worth up to $600M in product revenues over the life of the contract

Genfit SA (France)

BioMerieux-Pierre Fabre and Laboratoires Fournier (France)

US$8.8

Three-year research collaboration with BioMerieux for the identification of the molecular mechanisms of action of new drug candidates for the treatment of cardiovascular diseases; and a deal with Fournier for five years calling for the identification of new therapeutic targets in the field of metabolic diseases; the two deals provide Genfit with guaranteed research and development funding of at least US$8.8M over five years; Genfit also is entitled to possible milestones and royalties

Genicon Sciences Corp.

Genomics Institute of the Novartis Research Foundation

Multiyear agreement to employ Genicon's Resonance Light Scattering technology for use in GNF's internal proteomic microarray research; the two parties will further develop and commercialize RLS technology in conjunction with GNF's proteomic microarray technologies for the discovery of new drugs and drug targets

ImmunoGen Inc. (IMGN)

Boehringer Ingelheim International GmbH (Germany)

Agreement to develop a less toxic cancer therapeutic using ImmunoGen's Tumor-Activated Prodrug technology; Boehringer Ingelheim gains exclusive worldwide rights to commercialize resulting products; it also gains responsibility for manufacturing, development and marketing; ImmunoGen gains responsibility for manufacturing preclinical and initial clinical materials for manufacturing payments

Inex Pharmaceuticals Corp. (Canada; TSE:IEX)

GlaxoSmithKline plc (UK)

$36

Licensing agreement for the Transmembrane Carrier System for GlaxoSmithKline to make targeted cancer drugs; GSK will pay Inex $36 million in up-front and milestone fees; Inex also will receive royalties; GSK is responsible for all development costs

Jerini AG (Germany)

Aventis Pharma AG (Germany)

Product development and licensing agreement for the compound Icatibant; Jerini gains exclusive, worldwide, royalty-bearing rights to develop Icatibant in human health treatment

Labopharm Inc. (Canada; TSE:DDS)

Aventis Pharmaceuticals Inc. (unit of Aventis Pharma AG; Germany)

Licensing agreement to incorporate Labopharm's controlled-release technology, Contramid, into Allegra, a product for seasonal allergic rhinitis; Labopharm will receive milestone payments and potential royalties on product sales of the new formulations

LifeSpan BioSciences Inc.

Wyeth-Ayerst Laboratories (division of American Home Products Corp.)

Subscription agreement to LifeSpan's G protein-coupled receptor database

Maxygen Inc. (MAXY)

Aventis Pasteur (France; unit of Aventis SA)

$60

Three-year alliance to develop improved vaccines for a specific, unnamed target; Maxygen will receive license fees, full research and development funding, minimum annual royalties, and potential milestone and royalty payments on product sales; Aventis gains exclusive worldwide rights to commercialize the vaccines

MultiCell Technologies Inc. (subsidiary of Exten Industries Inc.; EXTI)

Pfizer Inc.

Collaborative research agreement involving the validation of MultiCell's immortalized liver cells to predict toxicological and therapeutic properties of drug candidates

Myogen Inc.

Abbott Laboratories Inc.

Agreement for exclusive worldwide rights to develop and take to market the endothelin receptor antagonist BSF 208075; Myogen will provide undisclosed up-front money and milestone payments, as well as royalties

Myriad Genetics Inc. (MYGN)

Fleury Laboratories (Brazil)

Collaboration to market Myriad's predictive medicine products throughout Brazil; the program will focus initially on cancer, with BRACAnalysis, Colaris and Myriad's new Melaris predictive medicine products

NeoOncoRx Inc. (unit of NeoTherapeutics Inc.; NEOT)

Bristol-Myers Squibb Co.

Agreement to develop Elsamitrucin, which induces single-strand DNA breaks; NeoOncoRx gains worldwide rights to develop and market the product

Orchid BioSciences Inc. (ORCH)

GlaxoSmithKline plc (UK)

Agreement to collaborate on a genome-wide validation of single nucleotide polymorphisms for pharmacogenetic studies; Orchid will develop SNP assays and will conduct ultra-high-throughput genotyping analyses; GlaxoSmithKline will select SNP candidates from Orchid's design database

Oxford GlycoSciences plc (UK; LSE:OGS; OGSI)

Teva Pharmaceutical Industries Ltd. (Israel)

Exclusive agreement for the marketing and distribution of Vevesca in Israel; financial terms were not disclosed

Paladin Labs Inc. (Canada; TSE:PLB)

Novartis Pharmaceuticals Canada Inc. (Canada)

Agreement in which Paladin Labs acquires the Canadian rights to Rogitine, which is indicated to prevent and control hypertensive episodes in patients with pheochromocytoma

SomaLogic

Mitsui & Co. Ltd. (Japan)

Collaboration to identify potential aptamer customers in Asia; Mitsui will initiate and negotiate agreements with potential purchasers who will provide protein targets for SomaLogic to use in the generation of aptamers for its research proteomics and clinical diagnostic arrays; Mitsui also made an equity investments in SomaLogic

Wilex AG (Germany)

Bayer Corp.

License, sublicense and option agreement with Bayer's diagnostics group to obtain certain rights under Bayer's MN patent portfolio; Wilex receives certain intellectual property rights that protect its G250 antibody; Bayer also granted to Wilex option rights to develop certain other antibodies targeting the MN antigen, as well as certain diagnostic option rights

October - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Accelrys (subsidiary of Pharmacopeia Inc.; PCOP)

GlaxoSmithKline plc (UK)

Collaboration to produce software that enables GSK scientists to access, analyze and visualize chemical and biological data stored on its research and development databases

Atrix Laboratories Inc. (ATRX)

Fujisawa Healthcare Inc.

$25

Licensing agreement for North American rights to Atrix's topical acne treatment, Atrisone; Fujisawa will pay Atrix up to $25M in license fees, research and development support and milestone payments; Atrix will manufacture Atrisone and will receive a manufacturing margin, as well as royalties

atugen AG (Germany)

AstraZeneca plc (UK)

One-year collaboration to use atugen's GeneBloc technology to increase efficiency of target validation and drug development in a number of major disease areas; atugen will retain all rights to GeneBlocs developed and will have an option to license intellectual property generated

Avant Immunotherapeutics Inc. (AVAN)

DynPort Vaccine Co. LLC (a joint venture of DynCorp and Porton International Inc.)

License agreement giving DynPort Vaccine exclusive rights to use certain components of Avant's vaccine technology; DynPort will advance the development of vaccines and other products for the government to protect against biological warfare agents; Avant is entitled to license fees, milestones and royalties

BioVex Ltd. (UK)

AstraZeneca plc (UK)

Collaborative agreement in the area of gene target validation; AstraZeneca will evaluate the ability of BioVex's NeuroVEX vectors to efficiently transduce the cells and tissues of the nervous system in order to study the function of genes that may be targets for the therapy of neurodegenerative disorders

Cambridge Antibody Technology plc (UK; CATG; LSE:CAT)

Merck & Co. Inc.

Five-year collaboration and license agreement for development of products for a target involved in HIV; Merck will provide HIV biology work and CAT will provide its human phage antibody libraries; Merck gains exclusive rights to resulting products; CAT will receive an up-front technology access fee, milestones and potential royalties on the sale of products

Cell Therapeutics Inc. (CTIC)

Natural Pharmaceuticals Inc.

Supply agreement under which NPI will provide paclitaxel to CTI

Ciphergen Biosystems Inc. (CIPH)

Pfizer Inc.

Agreement to discover proteins in serum from rat models and evaluate the importance of such proteins as biomarkers associated with drug safety

CombiMatrix Corp. (subsidiary of Acacia Research Corp.; ACRI)

Marubeni Japan (Japan)

Joint venture agreement focused on development and licensing opportunities for CombiMatrix's biochip technology with pharmaceutical and biotechnology companies in the Japanese market

Corixa Corp. (CRXA)

Amersham Health

$25

Amersham will handle the marketing of Bexxar in Europe; it will purchase as much as $15M in Corixa stock and has an option to purchase another $10M in shares at a later time

CTI Technologies Inc. (subsidiary of Cell Therapeutics Inc.; CTIC)

Chugai Pharmaceutical Co. Ltd. (Japan)

$73

Licensing agreement for the development and commercialization of PG-TXL in several Asian markets; CTI will receive an up-front payment of $3M and four potential milestone payments totaling $16M, as well as royalties on sales in the markets of China, Malaysia, the Philippines and other countries; the remaining $54M will be paid for development-related expenses

Cytos Biotechnology AG (Switzerland)

Novartis Pharma AG (Switzerland)

CHF70 (US$42.25)

Research and license option agreements to develop therapeutic vaccines for allergy, rheumatoid arthritis and chronic nervous system disorders; upon exercise of the option, Cytos will receive research funding and milestone payments of up to US$42.25M, as well as sales royalties

De Novo Pharmaceuticals Ltd. (UK)

Roche Diagnostics Corp. (division of F. Hoffmann-La Roche Ltd.; Switzerland)

Technology development collaboration in the area of de novo drug design; De Novo will retain full commercial rights of the design platform, Skelgen II; Roche will receive certain rights to use Skelgen II in drug discovery

Dendreon Corp. (DNDN)

Gambro Healthcare Inc. (subsidiary of Gambro AB; Sweden)

Agreement to support the commercialization of Dendreon's therapeutic vaccines; Gambro's U.S. network of clinics will serve as cell collection centers and Gambro BCT's COBE Spectra Apheresis System will be used for the cell collection procedure

Discovery Partners International Inc. (DPII)

Merck & Co. Inc.

Multiyear agreement to design, develop and produce libraries of drug-like high purity chemical compounds for Merck

DNA Sciences Inc.

Bristol-Myers Squibb Co.

Partnership to investigate genetic variants within a potential gene target; DNA Sciences will use its high-throughput sequencing and genotyping facility to study the BMS gene in normal and affected disease populations

DoubleTwist Inc.

NV Organon (the Netherlands)

Licensing agreement for the Prophecy database and tools suite, the Prophecy ToolKit and Genomatix Promoter Resource Database

Elitra Pharmaceuticals Inc.

Merck & Co. Inc.

Agreement in which Elitra will provide a defined number of antibiotic targets that Merck will screen against its natural product and compound libraries; Merck will own worldwide rights to any resulting products; Elitra will receive an up-front payment and gets three years of research funding, as well as potential milestone payments and royalties

First Genetic Trust Inc.

GlaxoSmithKline plc (UK)

Research collaboration to study genetic variations that influence why some patients experience certain adverse reactions when taking medications while others do not; GlaxoSmithKline will conduct all analyses, while First Genetic Trust will provide secure genetic banking services, where biological samples and medical data can be stored

Flamel Technologies SA (France; FLML)

Merck & Co. Inc.

Licensing agreement for the application of Flamel's Micropump technology to an undisclosed class of pharmaceutical compounds

Forest Laboratories Inc. (NYSE:FRX)

Lipha SA (subsidiary of Merck KGaA; Germany)

Distribution, marketing, trademark license and supply agreement for the U.S. rights to acamprosate (Campral) for the treatment of alcohol addiction

Galapagos Genomics NV (Belgium)

Procter & Gamble Pharmaceuticals (division of The Procter & Gamble Co.)

Collaboration under which P&GP will use Galapagos' adenovirus technology as a tool to validate the utility of genes as new drug targets; Galapagos will supply adenoviral vectors containing human genes selected by P&GP

Genaissance Pharmaceuticals Inc. (GNSC)

Pfizer Inc.

Agreement to give Pfizer selected data from Genaissance's Hap Database, a collection of markers of gene variations, known as haplotypes

Genencor International Inc. (GCOR)

Dow Corning Corp.

$35

Collaboration to mesh each company's knowledge in biotechnology and silicon chemistry to create a Silicon Biotechnology platform; products derived from the collaboration will be jointly commercialized and profits will be shared; Dow will provide $12M up front, as well as research funding and milestone payments

IDEC Pharmaceuticals Corp. (IDPH)

Mitsubishi Pharma Corp. (Japan)

$35

Expanded agreement to develop IDEC-114 for psoriasis; Mitsubishi will help pay for clinical development and will conduct parallel clinical trials in Japan; the deal originally was worth $12M

Immusol Inc.

Novartis Pharma AG

$150

Five-year collaboration that calls for Immusol to deliver at least 50 targets to Novartis in the oncology area; Immusol will use its Inverse Genomics technology to discover de novo biologically validated targets for Novartis; Novartis will then develop compounds

InforMax Inc. (INMX)

Amersham Biosciences

Agreement for the exclusive distribution by Amersham of the InforMax desktop software products in Latin America

Inhale Therapeutic Systems Inc. (INHL)

R.W. Johnson Pharmaceutical Research Institute and the Janssen Research Foundation (subsidiaries of Johnson & Johnson)

Collaboration in which Inhale will use Inhance pulmonary delivery technology to develop formulations of inhaleable small-molecule compounds up to proof of concept; R.W. Johnson and Janssen will evaluate and develop tested formulas; Inhale will receive research and development funding, milestone payments and royalties

InterMune Inc. (ITMN)

Boehringer Ingelheim International GmbH (Germany)

Expanded partnership to include the development and commercialization of interferon gamma-1b for the treatment of ovarian cancer; previous indications were idiopathic pulmonary fibrosis, tuberculosis, systemic fungal infections, chronic granulomatous disease and osteoporosis

Interneuron Pharmaceuticals Inc. (IPIC)

J. Uriach & Cia. SA (Spain)

In exchange for an up-front payment, development milestones and royalty payments to Uriach, Interneuron gains worldwide marketing rights to dersalazine, except in Spain

Kosan Biosciences Inc. (KOSN)

Meiji Seika Kaisha Ltd. (Japan)

Research collaboration for Kosan's production of a polyketide in one of its hosts, and Kosan's development of a Meiji bacterium that produces a polyketide; Meiji will provide funding for the one-year agreement

Lexicon Genetics Inc. (LEXG)

Pfizer Inc.

Nonexclusive internal research licensing agreement for a patent covering the use of Lexicon's isogenic DNA technology in gene targeting

LifeSpan BioSciences Inc.

Aventis Pharma (France)

Agreement in which Aventis became the sixth subscriber to LifeSpan's database on expression and localization of G protein-coupled receptors

Lorus Therapeutics Inc. (Canada; OTC BB:LORFF; TSE:LOR)

Faulding (Canada) Inc.

Exclusive seven-year distribution agreement in Latin America in which Faulding will market and sell Virulizin to treat malignant melanoma in Mexico; Lorus will receive royalties on sales and will be responsible for manufacturing

MediChem Life Sciences Inc. (MCLS)

Pharmacia Corp.

Two-year medicinal chemistry agreement in which MediChem will commit resources for drug discovery in collaboration with Pharmacia's in-house researchers; MediChem will be paid for its research and will receive royalties on resulting products

Novelos Therapeutics Inc.

HealthCare Asia Pharmaceuticals Inc. (Hong Kong)

Collaboration under which HealthCare Asia will develop and commercialize BAM-205 for hepatitis B and C in China

Orchid Biosciences Inc. (ORCH)

MiraiBio Inc.

Multiyear marketing agreement for the SNPstream MT product; MiraiBio gained nonexclusive worldwide rights to market the genotyping consumables and software developed by Orchid; Orchid retains the rights to distribute the system

Palatin Technologies Inc. (AMEX:PTN)

Serono Pharmaceutical Research Institute (research center of Serono SA; Switzerland)

Palatin will use Midas to generate compounds in support of Serono's research programs; financial details were not disclosed

Pharmacopeia Inc. (PCOP)

Boehringer Ingelheim GmbH (Germany)

Agreement to provide Boehringer with tools to test compounds against an undisclosed target; Pharmacopeia will receive a fixed up-front fee and success-based payments

Progenics Pharmaceuticals Inc. (PGNX)

UR Labs Inc.

Agreement acquiring the rights to the pain-related drug methylnaltrexone, which is entering Phase II trials

Quark Biotech Inc.

AstraZeneca plc (UK)

Agreement to search for cancer drug targets using QBI's BiFar technology; AstraZeneca will have the right to license a certain number of target genes and proteins for development; it has exclusive worldwide rights to commercialize products generated from the collaboration; QBI will receive research and development funding and milestones payments, as well as royalties

Proteome Systems (Australia)

Alpha Innotech Corp.

Agreement under which Alpha Innotech will manufacture its Alphalmager and FluorChem imaging systems for incorporation with Proteome Systems' ProteomeIQ integrated proteomics platform

Rosetta Biosoftware

GlaxoSmithKline plc (UK)

Licensing agreement for the Rosetta Resolver Software Development Kit version 2.0

Sequitur Inc.

Procter & Gamble Pharmaceuticals Co.

Agreement giving P&G access to Sequitur's functional genomics technology, with Sequitur performing biological screening and providing its antisense compounds and methods to P&G target validation studies

Sunesis Pharmaceuticals Inc.

Chiesi Farmaceutici S.p.A. (Italy)

$22-$30

Research collaboration to discover and develop small molecules that inhibit a well-validated protein-protein target involved in immunological diseases; Sunesis will receive up-front payments, research and development milestones and royalty payments based on sales; Chiesi will have an exclusive option to an exclusive license to develop and market any resulting products in Europe and Latin America; deal could be worth between $22M and $30M

Targesome Inc.

Merck KGaA (Germany)

Research and collaboration agreement in which the companies will evaluate the potential of combining Merck's small-molecule antiangiogenesis compounds with Targesome's nanoparticle technology to make new drugs for cancer and macular degeneration

Third Wave Technologies Inc. (TWTI)

Otsuka Pharmaceutical Co. Ltd. (Japan)

Marketing and distribution agreement under which Otsuka will distribute Invader research products in Japan and other countries in the Far East, Southeast Asia and the Middle East; Otsuka also will market the product and provide technical support

Valentis Inc. (VLTS)

Pfizer Inc.

Nonexclusive license agreement for Valentis' GeneSwitch gene regulation technology to be used for research purposes

Viragen Inc. (AMEX:VRA)

Tradeway Inc.

$255

Agreement in which Tradeway will distribute Multiferon, Viragen's natural alpha interferon product; Tradeway initially will purchase $5M of Viragen's product to complete the regulatory process in Taiwan; following approval, Tradeway will purchase an additional $250M of the drug over a five-year period

ViroLogic Inc. (VLGC)

F. Hoffmann-La Roche Ltd. and Trimeris Inc. (TRMS)

Expanded agreement to use ViroLogic's HIV resistance testing technology in the development of T-20 and T-1249, members of a class of antiviral agents called fusion inhibitors

Weston Medical Group plc (UK; LSE:WMG)

Chugai Pharmaceutical Co. Ltd. (Japan)

Option and licensing agreement for access to Weston's Intraject needle-free drug delivery technology for the administration of a therapeutic product; Weston will receive an up-front fee and milestone payments, as well as royalties

Xerion Pharmaceuticals AG (Germany)

Byk Gulden (unit of Altana AG, Germany)

Target validation agreement in which Xerion will use its XCALIbur technology for analysis; Byk Gulden will provide target proteins important to diseases such as cancer and inflammation

September - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Array BioPharma Inc.

Takeda Chemical Industries Ltd. (Japan)

Agreement to develop small-molecule drug leads; Array could receive milestones and royalties based on sales of products resulting from the collaboration

Bioreason Inc.

Warner-Lambert Co. (subsidiary of Pfizer Inc.)

Licensing agreement for Bioreason's software systems, DataPharmer, Lead-Pharmer and Drug-Pharmer

Bresagen Ltd. (Australia; BSGNY)

ProGen Industries Ltd. (Australia)

Manufacturing supply agreement to produce bacteria containing equine growth hormone, somatotropin; the hormone will be purified by BresaGen and formulated into EquiGen

Bresagen Ltd. (Australia; BSGNY)

Image-Guided Neurologics Inc.

Agreement to produce and distribute a specialized catheter intended to be used for delivery of cells into the brain

CeNeS Pharmaceuticals plc (UK; LSE:CEN)

International Processing Corp.

Alliance to co-promote CeNeS' oral sustained-release drug delivery technology in the U.S.

Connetics Corp. (CNCT)

Miza Pharmaceuticals Inc. (Canada)

Manufacturing and supply agreement for two of Connetics' branded products, Luxiq and Olux foams, for the dermatology market

Connetics Corp. (CNCT)

Mipharm SpA (Italy)

Product licensing agreement that grants Mipharm commercial rights in Italy for Connetics' OLUX topical treatment for moderate to severe scalp dermatoses, permethrin foam for the treatment of scabies, and Hexifoam, a hand disinfectant; Connetics will receive up-front license fees, milestone payments and royalties on future product sales

Dendreon Corp. (DNDN)

Bayer Corp.

Agreement to license two tumor antigens, carcinoembryonic antigen and MN antigen, for use in Dendreon's therapeutic cancer vaccines

Evotec OAI (Germany; Neuer Markt:EVT)

Novartis Pharma AG (Switzerland)

License and technology agreement entitling Evotec to deploy, further develop and exclusively market Novartis' AIDA on-bead chemistry in combination with Evotec's PICKOscreen on-bead screening technology for drug discovery

FibroGen Inc.

Sankyo Co. Ltd. (Japan)

Three-year agreement to discover and develop treatments for fibrotic disorders to include diabetic nephropathy, retinopathy and forms of renal fibrosis, pulmonary fibrosis, organ transplant rejection, liver fibrosis and atherosclerosis

Gene Logic Inc. (GLGC)

UCB Research (division of UCB Pharma; Belgium)

Subscription agreement to the BioExpress Module of Gene Logic's GeneExpress suite; UCB also purchased an exclusive license to additional asthma and allergy-related gene targets and associated gene expression data

ImClone Systems Inc. (IMCL)

Bristol-Myers Squibb Co.

$1B

Agreement to help develop and promote the cancer drug, IMC-225; $1B will come in development milestones; Bristol-Myers also is buying about 14.4M shares for $1B from stockholders

Inhibitex Inc.

Wyeth Lederle Vaccines (unit of American Home Products Corp.)

$23

Research and commercial partnership for the development of human vaccines targeting Staphylococcus aureus and Staphylococcus epidermidis; Wyeth Lederle gains an exclusive license to Inhibitex's MSCRAMM protein technology in return for up-front, milestone and research and development payments, as well as royalties

InKine Pharmaceutical Co. Inc. (INKP)

Zeria Pharmaceutical Co. Ltd. (Japan)

$2.5

Licensing agreement for exclusive rights to InKine's Visicol in Japan; InKine will receive an up-front license fee of $500,000 and an additional $2M in fixed license fees upon meeting milestones; Zeria will be responsible for all development costs and will pay royalties to InKine

InterMune Pharmaceuticals Inc. (ITMN)

Eli Lilly and Co.

$50

Agreement for rights to oritavancin; Eli Lilly will receive $50M up front, as well as potential milestone and royalty payments; InterMune gains exclusive worldwide rights to develop, manufacture and commercialize oritavancin

Invitrogen Corp. (IVGN)

American Home Products Corp.

Collaborative research service agreement in which Invitrogen will use its cDNA library and high-throughput gene isolation capabilities to provide full-length clones of genes targeted by Wyeth-Ayerst Laboratories, the pharmaceutical division of AHP

Lexicon Pharmaceuticals (subsidiary of Lexicon Genetics Inc.; LEXG)

Pfizer Inc.

Pfizer gained nonexclusive use of a library of chemical compounds from Lexicon

LifeSpan BioSciences Inc.

Sanofi-Synthelabo (France)

Agreement in which Sanofi subscribed to LifeSpan's database of information on the expression and localization of G protein-coupled receptors

Memory Pharmaceuticals Corp.

Bayer AG (Germany)

Exclusive worldwide license agreement for the rights to commercialize and market MEM 1003 to treat dementia; Memory will pay Bayer royalties, in addition to up-front and milestone payments

Millennium Pharmaceuticals Inc. (MLNM)

Bayer AG

Expanded collaboration for the development of compounds to include three additional indications, thrombosis, urinary incontinence and benign prostatic hypertrophy; the companies also discontinued efforts in osteoporosis and liver fibrosis

Morphotek Inc.

Wyeth-Ayerst Laboratories (division of American Home Products Corp.)

Collaborative research agreement in which Morphotek will apply its Direct-Line technology for the development of cell lines for Wyeth's internal research and development programs in oncology

Nastech Pharmaceutical Co. Inc. (NSTK)

G. Pohl Boskamp GmbH & Co. (Germany)

Exclusive licensing agreement for development and European commercialization rights to Nastech's intranasal morphine for treatment of moderate to severe pain; Nastech will receive an up-front license fee, milestone payments and double-digit royalties for achieving certain goals

NeoOncoRx Inc. (subsidiary of NeoTherapeutics Inc.; NEOT)

Johnson Matthey plc (UK)

Agreement for the worldwide rights to develop and market satraplatin for cancer; NeoOncoRx intends to initiate Phase III trials for prostate cancer in early 2002

Peregrine Pharmaceuticals Inc. (PPHM)

Medipharm Biotech Co. (China)

$1.8

Development agreement for Peregrine's tumor necrosis therapy; Peregrine will provide product development and contract manufacturing services to Medipharm, pending Chinese approval; the contract is worth $1.8M

Phytomedics Inc.

Bristol-Myers Squibb Co.

Agreement to test the production of therapeutic proteins using Phytomedics' plant-based recombinant proteins secretion technology

ProCorde GmbH (Germany)

Aventis Pharma Deutschland GmbH (unit of Aventis SA; Germany)

Two-year cooperation agreement to identify new therapeutic target proteins for the development of pharmaceuticals for heart and vascular diseases; ProCorde will receive a basic fee, as well as potential milestones

RTP Pharma Inc.

Baxter Healthcare Corp.

Exclusive agreement to collaborate on the use of RTP's insoluble drug delivery technology for the formulation of injectable medications; RTP will receive license fees, milestone payments and royalties; Baxter has exclusive manufacturing rights to the products

Tripos Inc.

AstraZeneca plc (UK)

Multiyear, multimillion-dollar agreement to provide the Sybyl suite of in silico drug discovery technologies to AstraZeneca's life scientists worldwide

Tripos Inc. (TRPS)

Schering AG (Germany)

Agreement to build a global Enhanced Chemical Information Management System that integrates Schering's compound research data and inventory data

ViroPharma Inc. (VPHM)

Aventis Pharmaceuticals (U.S. division of Aventis Pharma AG; Germany)

$25

Co-development, co-promotion agreement for Picovir; ViroPharma will receive $25M as an initial payment, plus undisclosed milestone payments; profits will be split 55% for Aventis and 45% for ViroPharma

Vysis Inc. (VYSI)

Roche Diagnostics Corp. (division of F. Hoffmann-La Roche Ltd.; Switzerland)

Exclusive license agreement that will provide Vysis access to genetic markers that may allow for the unique identification of fetal cells in a maternal blood sample

ZymoGenetics Inc.

Serono SA (Switzerland)

$52.5

Agreement for the development and commercialization of two preclinical candidates discovered by ZymoGenetics, TACI and BCM; the companies will share research and development expenses everywhere but Japan, where Serono will cover all expenses

August - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Affitech (Norway)

Nycomed Amersham Imaging (UK)

Research agreement for the discovery of fully human antibodies for imaging applications; Affitech will receive milestone and royalty payments

Atrix Laboratories Inc. (ATRX)

Faulding Pharmaceuticals (division of F.H. Faulding & Co. Ltd.; Australia)

Exclusive licensing deal for Australian and New Zealand rights to its three Leuprogel products for inhibiting the growth of hormone-responsive advanced prostate cancer

BioDiscovery Inc.

Syngenta AG's Torrey Mesa Research Institute (Switzerland)

Licensing agreement for BioDiscovery's GeneSight software for the analysis of gene expression data generated by the institute

Biofrontera Pharmaceuticals AG (Germany)

Janssen Pharmaceutica NV (Belgium)

Research collaboration to explore the benefits of nicotinic modulation in the treatment of Alzheimer's disease; collaboration will focus on Reminyl

Cellegy Pharmaceuticals Inc. (CLGY)

PanGeo Pharma Inc. (Canada; TSE:PIL)

Long-term agreement under which PanGeo will manufacture Cellegy's Tostrex testosterone gel; Cellegy will supply PanGeo with Tostrex over a five-year period following final FDA approval

Cellegy Pharmaceuticals Inc. (CLGY)

Ventiv Integrated Solutions

$10

Agreement in which Ventiv will provide marketing and sales solutions for Anogesic and will cover prelaunch and early launch expenses, up to $10M, through a loan to Cellegy; the loan will be repaid through Anogesic revenues; Ventiv will receive a large portion of revenues early on, but Cellegy will take a larger portion over time; Ventiv also will receive undisclosed royalties over the six-year deal

Coley Pharmaceutical Group Inc.

Aventis Pharma AG (Germany)

Agreement for asthma and allergic rhinitis in which Aventis gains a worldwide license to CpG 9328, and up to three other molecules; Coley will receive milestone payments, and double-digit royalties on any product sales

Compugen Ltd. (Israel; CGEN)

Novartis AG (Switzerland)

Agreement to use Compugen's technology services to accelerate identification of drug targets based on the analysis of fundamental gene and protein data

Crucell NV (the Netherlands; CRXL)

Centocor Inc. (subsidiary of Johnson & Johnson)

Agreement allowing Centocor to develop and market Crucell's anticancer antibodies everywhere except Europe; Centocor will pay Crucell annual milestone payments and royalties; Crucell will have exclusive commercialization rights in Europe

Cypress Bioscience Inc. (CYPB)

bioMerieux Pierre Fabre (France)

License agreement that provides Cypress with an exclusive license to develop and sell any products with the compound milnacipran as an active ingredient, for the treatment of fibromyalgia syndrome and related chronic pain syndromes in the U.S. and Canada; Cypress will pay an up-front payment, and possibly milestones and royalties

Deltagen Inc. (DGEN)

Eli Lilly & Co.

Agreement to use Deltagen's technology to evaluate and potentially develop and commercialize therapeutic secreted proteins for Lilly; it includes certain acquisition, co-promotion, co-marketing and profit-sharing options for Lilly; Deltagen will receive co-promotion, co-development and profit-sharing rights as well

Demegen Inc. (OTC BB:DBOT)

Dow Chemical Co.

Research and licensing option agreement to design new products for use in industrial and commercial applications

Dendreon Corp. (DNDN)

Kirin Brewery Co. Ltd. (Japan)

$10

Expanded agreement providing Kirin with extensive clinical development and regulatory support aimed at seeking marketing approval in Asia of Dendreon's leading cancer vaccine candidates, Provenge and Mylovenge; Dendreon received a $10M payment from Kirin

diaDexus Inc.

Fujirebio Inc. (Japan)

Research and license collaboration to develop and sell cancer diagnostic tests in Japan; diaDexus will receive licensing fees and funding from Fujirebio for three years

EntreMed Inc. (ENMD)

Royalty Pharma AG (Switzerland)

$24.3

EntreMed sold its rights to future royalties from the sales of Thalomid (thalidomide) to Royalty Pharma for $24.3M; EntreMed may receive another $3M if certain sales milestones are achieved

Evotec OAI (Germany; Neuer Markt:EVT)

Pharmacia Corp.

Four-year contract under which Evotec will provide high-quality libraries for pharmaceutical screening and receive program and milestone fees on any product that comes out of the collaboration

Exelixis Inc. (EXEL)

Elan Corp. plc (Ireland)

Agreement to make a high-throughput, small-molecule screening library; in the three-year deal, Elan will pay Exelixis an undisclosed milestone fee, and more money as compounds are delivered

Genzyme Canada Inc. (Canada; subsidiary of Genzyme Corp.; GENZ)

Theramed Corp. (subsidiary of Meta Health Services Inc.; Canada)

Three-year exclusive agreement to jointly market Genzyme's Thyrogen recombinant thyroid-stimulating hormone following Canadian regulatory approval

Genzyme Corp. (GENZ)

Pharming Group NV (the Netherlands)

Agreement in which Genzyme will fully fund production of the transgenic enzyme being used to treat nine patients with Pompe disease

Hyseq Inc. (HYSQ)

Kirin Brewery Co. Ltd. (Japan)

Research and development collaboration in which Kirin will fund three years of research work at Hyseq and both companies will conduct research directed toward discovering proteins and antibodies for diseases; discoveries will be jointly owned and shared; Hyseq will have marketing rights in North America, and Kirin will have marketing rights in Asia, New Zealand and Australia; they will be shared in the rest of the world

Isis Pharmaceuticals Inc. (ISIP)

Eli Lilly & Co.

$400

Agreement focused on Isis' antisense technology, specifically ISIS 3521 for non-small-cell lung cancer; the deal includes a possible $200M in milestones, $100M in loans, $25M in up-front fees, research funding, and $75M in equity investments, as well as royalties; the companies also will collaborate to discover antisense drugs for metabolic and inflammatory disease

Lexicon Genetics Inc. (LEXG)

Merck & Co. Inc.

Licensing agreement for nonexclusive rights to Lexicon's gene-targeting technologies for use in Merck's internal research programs

Lexicon Genetics Inc. (LEXG)

GlaxoSmithKline plc (UK)

Multiyear, nonexclusive sublicense to use Lexicon's patented gene-targeting programs for GSK's internal research programs; Lexicon will receive an up-front technology and license fee

MacroMed Inc.

Novartis Pharma AG (Switzerland)

Multidrug feasibility agreement giving Novartis access to MacroMed's controlled-release technology, ReGel

Millennium Pharmaceuticals Inc. (MLNM)

Aventis Pharmaceuticals Inc.

$450

The companies have added 11 new discovery projects to their year-old $450M collaboration; they now have about 50 jointly funded discovery projects

Modex Therapeutics Ltd. (Switzerland; SWX:MDXN)

Serono SA (Switzerland)

CHF1 (US$0.59)

Second agreement for the engineering of a cell line for the production of a protein of commercial interest; the two-year program will be entirely funded by Serono with Modex earning milestone fees of up to CHF1M (US$585,133) and a percentage on future income

NeoGenesis Inc.

Mitsubishi-Tokyo Pharmaceuticals Inc. (Japan)

NeoGenesis will generate leads from a target supplied by Mitsubishi using its Automated Ligand Identification System and neoMorph library; NeoGenesis will receive discovery payments, as well as milestones and mid-range single-digit royalties

NeoGenesis Drug Discovery Inc.

Schering-Plough Corp.

$25

Expansion to their deal for antivirals, in which NeoGenesis gets a $5M equity investment from Schering-Plough, which also will provide research and development funding of about $4M per year for up to five years

Nexell Therapeutics Inc.

Baxter Healthcare Corp.

$4.3

Agreement under which Baxter will become the worldwide distributor of Nexell's cell processing products; Baxter will purchase certain assets and liabilities of Nexell's cell processing business, as well as worldwide sales, marketing and distribution rights for the related products for about $4.3M net, plus royalties

Norak Biosciences Inc.

Amersham Pharmacia Biotech Inc.

Collaboration in which Amersham will provide its LEADseeker Cell Analysis System and Norak will provide its Transfluor drug discovery technology to accelerate GPCR drug discovery

Orion Corp. (Finland)

Pharmacia Corp.

$30

Agreement to collaborate on the development and commercialization of deramciclane in the U.S.; Orion Pharma, a division of Orion, will receive $30M up front from Pharmacia, as well as milestone payments

Qiagen NV (the Netherlands)

Bayer AG (Germany)

Technology access and evaluation agreement in which Bayer will gain limited access to the ZeptoGene Workstation technology platform

Quintiles Transnational Corp. (QTRN)

Novia Pharmaceuticals Ltd. (Israel)

Alliance to provide preclinical services for Novia's lead AD4 compound to treat central nervous system disorders; Quintiles will make an investment in Novia and will receive an equity position and royalties

Sequenom Inc. (SQNM)

GlaxoSmithKline plc (UK)

Multimillion-dollar deal expected to result in the availability of 400,000 single nucleotide polymorphism assays by the end of the year

TransTech Pharma Inc.

Novo Nordisk A/S (Denmark)

Five-year agreement for TransTech to use its Translational Technology to turn out clinical candidates from Novo's targets; TransTech will receive an up-front payment in the deal, as well as research support, milestones and royalty payments; Novo gets an exclusive worldwide license to certain realized products

Vivalis (France)

Aventis Pasteur (France)

Research agreement covering a joint research program in the field of avian embryonic stem cells

XenoPharm Inc.

Bristol-Myers Squibb Co.

XenoPharm will evaluate developmental compounds using proprietary assays to determine their ability to induce the expression of drug metabolism enzymes typically found in the liver

July - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Amarin Corp. plc (UK; AMRN)

Elan Corp. plc (Ireland)

Partnership to establish a franchise in the therapeutic area of Parkinson's disease; Amarin gains exclusive U.S. marketing, sales and distribution rights to Permax tablets, and entered an option agreement to acquire the U.S. rights to Zelapar

Amersham Pharmacia Biotech

Nonlinear Dynamics Ltd. (UK)

Agreement for global distribution of Nonlinear's Progenesis 2D electrophoresis software package under APBiotech's Ettan brand

Antisoma plc (UK; ASOM; LSE:ASM)

W.C. Heraeus GmbH & Co. KG (Germany)

Cooperation and supply agreement for Thioplatin, a platinum-based compound used for killing cancer cells

Aventis Pharmaceuticals Inc. (NYSE:AVE)

Ajinomoto Co. (Japan)

Licensing agreement to develop and market AVE8062 designed to attack tumor cells; Aventis receives rights to develop and market the product in exchange for certain milestone payments, and potential royalty payments

Boston Probes Inc.

Diazyme Laboratories (subsidiary of General Atomics)

License and supply agreement for the development of single nucleotide polymorphism detection products that use peptide nucleic acid technology; agreement allows Diazyme to develop and market worldwide two PNA-based specific SNP kits to test for human blood coagulation disorders

CombiMatrix Corp. (unit of Acacia Research Corp.; ACRI)

Roche Diagnostics (Switzerland)

Nonexclusive worldwide license, supply, research and development agreement under which Roche will purchase, use and resell CombiMatrix's biochips and related technology for rapid production of customizable biochips; the deal includes a revenue-sharing arrangement and has a term of 15 years; Roche also will make minimum payments for three years

Chiron Corp. (CHIR)

Merck Frost Canada Ltd.

$50

Agreement to distribute Chiron's Menjugate vaccine in Quebec; the Quebec government is putting up C$75 (US$48.78M) for about 1.7M doses

Compugen Ltd. (CGEN)

Kyowa-Hakko Kogyo Co. Ltd. (Japan)

Agreement to license Gencarta, its annotated genome, transcriptome and proteome database and query tools

Corixa Corp. (CRXA)

Nycomed Amersham Imaging

Agreement in which Corixa's U.S. sales force will co-promote Metastron, developed by Nycomed for the palliation of metastatic bone pain; Corixa will receive financial incentives based on specified sales levels

Curis Inc. (CRIS)

Elan Corp. plc (Ireland)

$28

Joint venture, Curis Newco, to research and develop molecules that stimulate the hedgehog pathway; Curis will receive about a $4M equity investment and another $10M to fund research and development; Elan will contribute a similar amount of money to Curis Newco

deCode Genetics Inc. (DCGN)

F. Hoffmann-La Roche Ltd.

$300

Five-year agreement to develop DNA-based diagnostics, predisposition screening products and point-of-care informatics products

EpiVax Inc.

Beckman Coulter Inc.

Alliance to discover, develop and commercialize products and services for the identification of biological sequences with potential for activating the immune system; Beckman Coulter will market EpiVax epitope discovery services in the U.S., Canada and certain European countries

Exelixis Inc. (EXEL)

Bristol-Myers Squibb Co.

$200

Agreement in which Exelixis will identify and validate molecular targets that kill cancer cells; Bristol-Myers will take up the validation work in humans and pay $5M up front; it also will buy 600,600 shares of Exelixis stock at $33.30 per share, and will pay $3M per year for at least three years; agreement also includes milestone payments

Genome Therapeutics Corp. (GENE)

Wyeth-Ayerst Laboratories (unit of American Home Products Corp.)

Genomics-based research collaboration extended through December 2002 to cover the prevention and treatment of osteoporosis

Genzyme Transgenics Corp.

Fresenius AG (Germany)

$3.8

Fresenius exercised an option to gain additional rights to market recombinant human serum albumin in North America and Asia, excluding Japan

ICN Pharmaceuticals Inc. (NYSE:ICN)

F. Hoffmann-La Roche Ltd. (Switzerland)

Licensing agreement for Levovirin, a compound to treat hepatitis C; Roche will pay a one-time licensing fee and milestone payment, as well as royalties

Lexicon Genetics Inc. (LEXG)

NV Organon (the Netherlands)

Renewed and expanded OmniBank Universal agreement to include access to Lexicon's research program to study the physiological in vivo function of genes; Lexicon will receive annual technology access fees and research funding from Organon

Lexicon Genetics Inc. (LEXG)

Oriental Yeast Co. (Japan)

Extended and expanded marketing collaboration and distribution agreement, calling for Oriental Yeast to assist Lexicon in the promotion of its LexVision database to Japanese pharmaceutical companies and in marketing Lexicon's drug target validation technologies in the Japanese market

Metabolex Inc.

Pfizer Inc.

Realigned research partnership shifting away from a program focused on insulin-resistant genomics and toward one aimed at discovering drug targets related to insulin secretion; it includes a one-time payment to Metabolex of $6M

Microbiotix Inc.

Nissin Food Products Co. Ltd. (Japan)

Exclusive worldwide licensing agreement for a series of antiviral compounds, including NMSO3, an inhibitor of respiratory syncytial virus and adenoviruses

Microcide Pharmaceuticals Inc. (MCDE)

NAEJA Pharmaceutical Inc. (Canada)

Research and license agreement to develop and commercialize drugs based on NAEJA's azole antifungals and Microcide's fungal efflux pump inhibitor leads; agreement gives Microcide exclusive rights; NAEJA will receive milestone payments and royalty payments

M-phasys GmbH (Germany)

Bayer AG (Germany)

Two-year collaborative agreement to discover active ingredients acting on membrane protein targets

Neurochem Inc. (Canada; TSE:NRM)

Nycomed Amersham Imaging

Collaboration to create a diagnostic product for Alzheimer's disease; the deal includes milestone payments to Neurochem, and royalties from a potential product

Neurocrine Biosciences Inc. (NBIX)

GlaxoSmithKline plc (UK)

$25.5

Research, development and commercialization agreement for corticotropin-releasing factor receptor antagonists; Neurocrine will receive up-front fees and early milestone payments totaling $25.5M, as well as annual fees for four years and further milestone payments

Novasite Pharmaceuticals Inc. (subsidiary of Applied Molecular Evolution Inc.; AMEV)

Aventis Pharma

Evaluation agreement to conduct a pilot screening project using Novasite's Expanded Target Drug Discovery technology platform

Novavax Inc. (AMEX:NOX)

King Pharmaceuticals Inc.

Expanded licensing agreement for Novavax's topical estrogen replacement therapy, Estrasorb, which grants King exclusive rights for promotion, marketing and distribution in Canada and five European countries

Procyon BioPharma Inc. (Canada; TSE:PBP)

Goodwin Biotechnology Inc. and Multiple Peptide System

Manufacturing supply agreement with Goodwin to produce the lead candidate for Procyon's ANA anticancer platform technology, chimeric monoclonal antibody c-2C5, and with Multiple Peptide System for the production of cGMP PCK3145

Protein Design Labs Inc. (PDLI)

American Home Products Corp.

Two-year patent rights agreement for antibodies to an undisclosed target antigen; PDL receives a nonrefundable, noncreditable up-front license fee, and AHP obtains a worldwide, nonexclusive license to the antibodies

QLT Inc. (Canada; QLTI; TSE:QLT)

Novartis Ophthalmics (the eye care unit of Novartis AG; Switzerland)

C$15 (US$9.7)

Expanded alliance to co-develop photodynamic therapy with verteporfin to treat skin cancer and other dermatological conditions; Novartis will fund development costs up to C$15M, after which they will share costs and profits; QLT can receive milestones of C$2.5M for the first regulatory filing and approval

Rigel Pharmaceuticals Inc. (RIGL)

Novartis Pharma AG

Expanded agreement for Rigel to discover and develop small-molecule compounds that inhibit angiogenesis as a therapy for cancer; Rigel will receive a $4M up-front cash payment, milestones and royalty payments

Sangamo BioSciences Inc. (SGMO)

Pharmacia Corp.

Agreement to develop cell lines for small-molecule screening; Sangamo will receive an up-front payment, research funding, product development milestones and royalties

Seattle Genetics Inc. (SGEN)

CLB-Research and Development (the Netherlands)

Agreement to license certain monoclonal antibodies that target cancer and immunological disease; Seattle Genetics will have development, manufacturing and worldwide commercialization rights to therapeutic products derived from the antibodies

SkyePharma plc (UK; SKYE; LSE:SKP)

Elan Pharma International Ltd. (affiliate of Elan Corp. plc; Ireland)

$23

Licensing agreement for marketing rights to DepoCyte in Europe and the Philippines; SkyePharma received a $10M signing fee and will receive milestone payments that could reach $13M

SkyePharma plc (UK; SKYE; LSE:SKP)

Nippon-Shinyaku Co. Ltd. (Japan)

Marketing and distribution rights in Japan and Taiwan for DepoCyt, SkyePharma's treatment for lymphomatous and neoplastic meningitis

Visible Genetics Inc. (Canada; VGIN)

Abbott Laboratories Inc.

Agreement under which VGI will assist Abbott by providing HIV resistance testing in two clinical studies involving Abbott's protease inhibitor, Kaletra

Weston Medical Group plc (UK; LSE:WMG)

Abbott Laboratories Inc.

Abbott has an option for exclusive rights to use the Intraject technology for up to 11 therapeutic targets in the next 10 years; Weston would receive up-front fees, milestone payments and royalties

XTL Biopharmaceuticals Ltd. (Israel; LSE:XTL)

Dong-Wha Pharmaceutical Industrial Co. Ltd. (South Korea)

Collaborative agreement to evaluate small-molecule compounds to treat hepatitis C; Dong-Wha will retain development and marketing rights in Korea; XTL has the option to acquire those rights in the rest of the world

June - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Actelion Ltd. (Switzerland)

R.W. Johnson Pharmaceutical Research Institute (division of Ortho-McNeil Pharmaceutical Inc.)

Extended collaboration for a third year; Actelion will continue to combine its base in vascular endothelium biology to discover compounds targeting vascular endothelium; Johnson & Johnson will develop and commercialize any new drugs arising from the project

BioVex Ltd. (UK)

Aventis Pharma AG (Germany)

Evaluation agreements in which BioVex will use GenTest to provide Aventis with NeuroVEX vectors; Aventis will evaluate their ability to transduce cells and tissues of the nervous system; Aventis also will evaluate ImmunoVEX vectors as a delivery vehicle for dendritic cells

Celera Genomics Inc. (NYSE:CRA)

Yamanouchi Pharmaceutical Co. Ltd. (Japan)

Five-year subscription agreement to the Celera Discovery System and use of Celera's database products and other discovery tools

Cerep (France)

Aventis Pharma AG (Germany)

Three-year drug discovery agreement in which Cerep will make its drug discovery technology platform available to Aventis for preclinical studies of new compounds

ChemBridge Corp.

Sumitomo Pharmaceuticals Co. Ltd. (Japan)

Agreement to provide Sumitomo nonexclusive access to ChemBridge's Pharmacophore combinatorial lead discovery library

Cephalon Inc. (CEPH)

Orphan Australia Pty. Ltd. (Australia)

Orphan gained Australian and New Zealand sales, marketing and distribution rights for Actiq

Cepheid Inc. (CPHD)

BioSynTech Sdn Bhd (Malaysia)

Exclusive distribution agreement for the marketing of Smart Cycler system in Malaysia and Singapore

Chiron Corp. (CHIR)

Bayer Corp.

Bayer acquired certain development, manufacturing and sales agency rights to immunodiagnostic products for the detection of hepatitis C and HIV antibodies

Compugen Inc (CGEN).

Sigma-Genosys

Alliance to design and manufacture OligoLibraries designed to provide access to oligonucleotide collections for high-throughput analysis of gene function

Cytokinetics Inc.

GlaxoSmithKline plc

$50

Collaboration to develop novel small-molecule therapeutics targeting mitotic kinesins for applications in the treatment of cancer and other diseases

DoubleTwist Inc.

Boehringer Ingelheim International GmbH (Germany)

Licensing agreement for DoubleTwist's Clustering and Alignment Tools

Dragon Pharmaceuticals Inc. (Canada; OTC BB:DRUG)

Transworld Pharmaceuticals Corp. (Portugal) and Renapharm AB (Sweden)

Agreement giving Dragon sole worldwide manufacturing rights and exclusive marketing rights in Asia to a novel, slow-release formulation of erythropoietin; Transworld will have exclusive marketing rights outside Asia

EntreMed Inc. (ENMD)

Aventis Pharmaceuticals Inc.

Collaboration on Phase II studies in patients with hormone-refractory prostate cancer

Galapagos Genomics NV (Belgium)

Bayer Yakuhin (Japanese affiliate of Bayer AG; Germany)

Research collaboration to identify the function of proteins encoded by newly discovered genes associated with asthma

Genentech Inc. (NYSE:DNA)

Schwarz Pharma AG (Germany)

Agreement for Genentech to reacquire rights to two growth hormone products, Nutropin AQ and Nutropin Depot; Schwarz will return development and marketing rights in Europe and certain other countries outside Canada, the U.S., China and Japan

Genetronics Biomedical Corp. (AMEX:GEB)

Boehringer Ingelheim GmbH (Germany)

Material transfer and evaluation agreement allowing BI to investigate the use of Genetronics' electroporation technology for use in cardiovascular gene therapy

Illumina Inc. (ILMN)

GlaxoSmithKline plc (UK)

Commercial agreement to provide single nucleotide polymorphism genotyping services on a sample collection provided by GSK; Illumina will use its BeadArray technology to determine the frequency of specified SNPs in the sample set

ImmunoGen Inc. (IMGN)

BioInvent International AB (Sweden)

Manufacturing supply agreement to produce one of ImmunoGen's monoclonal antibodies

Ligand Pharmaceuticals Inc. (LGND)

TAP Pharmaceutical Products Inc.

$44

Three-year research and development agreement for selective androgen receptor modulators for indications such as hypogonadism, sexual dysfunction, osteoporosis, frailty and male hormone replacement therapy; the deal is worth up to $44M for Ligand in research funding and milestones

Meristem Therapeutics Inc. (France)

Solvay Pharmaceuticals Inc. (Belgium)

Exclusive licensing agreement for the use of Meristem's recombinant gastric lipase to treat digestive troubles linked with cystic fibrosis; Solvay will carry out and fund Phase IIb and Phase III trials and will market the drug worldwide; Meristem will receive an up-front payment, as well as milestone payments and royalties

NaPro BioTherapeutics Inc. (NPRO)

JCR Pharmaceuticals Co. Ltd. (Japan)

Exclusive development, supply and distribution agreement for NaPro's paclitaxel in Japan

NetGenics Inc.

Schering AG (Germany)

Partnership aimed at building a comprehensive corporate gene database with the goal of providing a single, central point of access to curated and annotated gene, sequence and expression data

Nexell Therapeutics Inc. (NEXL)

Baxter Healthcare Corp.

Nexell signed a letter of intent to transfer exclusive worldwide rights for sales, marketing and distribution of its cell-processing products to Baxter

Novirio Pharmaceuticals Ltd.

Sumitomo Pharmaceuticals Co. Ltd. (Japan)

$46

Development and distribution deal that gives Sumitomo marketing rights to LdT for hepatitis B in Japan, China, Taiwan and South Korea for $46M in up-front payments and milestones, as well as royalties on sales

Paradigm Genetics Inc. (PDGM)

Bayer AG (Germany)

$30

Extended and expanded research agreement to develop herbicides; the five-year deal, worth up to $30M, is an extension to a $40M deal signed in 1998

Peregrine Pharmaceuticals Inc. (PPHM)

Schering AG (Germany)

Peregrine took back the development of Oncolym from Schering AG and plans to move the technology forward on its own before seeking another partner

Pilot Therapeutics Inc.

Quintiles Transnational Corp.

Commercialization agreement for Pilot's lead product, PLT 3154, to treat asthma

Qiagen Genomics Inc. (unit of Qiagen NV; QGENF)

Shimadzu Corp. (Japan)

Nonexclusive license and purchase agreement calling for Qiagen to sell its Masscode system and license the related technology to Shimadzu for high-throughput single nucleotide polymorphism genotyping

Questcor Pharmaceuticals Inc. (AMEX:QSC)

Fabre Kramer Pharmaceuticals Inc.

Letter of understanding to jointly pursue worldwide development and commercialization of Hypnostat for insomnia and Panistat for panic disorders

Rosetta Inpharmatics Inc. (RSTA) and Agilent Technologies Inc. (NYSE:A)

Monsanto Co.

Licensing agreement for the Rosetta Resolver Gene Expression Data Analysis System

SafeScience Inc. (SAFS)

Elan Corp. plc (Ireland)

$17

Development agreement for SafeScience's lead candidate, GBC-590, in oncology; funding could result in Elan owning up to 11.6M shares of SafeScience

Symyx Technologies Inc. (SMMX)

Merck & Co. Inc.

Agreement to develop a Discovery Tools system for the discovery, identification and characterization of novel crystalline sale and polymorphic forms of drug candidates for use in clinical trials

The Medicines Co. (MDCO)

Grupo Ferrer Internacional SA (Spain)

Agreement for registration, distribution and promotion of Angiomax in Spain, Portugal, Greece and 18 Latin American markets; companies will share equally in sales revenue

Trimeris Inc. (TRMS)

Hoffmann-La Roche Inc.

Expanded agreement to discover and develop novel generations of HIV fusion inhibitor peptides

May - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Alliance Pharmaceutical Corp. (ALLP)

Baxter Healthcare Corp.

$30

Modified agreement for Oxygent development in which Baxter will make a $4M investment in Series F preferred stock, as well as an additional $3M investment later in May; Baxter must make an additional investment of $23M by the end of September

Antares Pharma Inc. (ANTR)

Pharmacia Corp.

License agreement for an undisclosed product using Antares' transdermal gel technology delivery system; Pharmacia gains exclusive rights for sales and marketing of the product for certain European territories

Applied Genetics Inc. Dermatics

Elan Corp. plc (Ireland)

Alliance to commercialize AGI Dermatics' Dimericine, which reverses the damage to skin DNA caused by solar ultraviolet exposure; companies will jointly develop the drug and will license marketing rights; Elan will make a $4M equity investments in AGI Dermatics, as well as additional equity investments at certain milestones

Astex Technology Ltd. (UK)

AstraZeneca AB (UK)

Structural biology research agreement to focus on solving novel cytochrome P450 crystal structures to be used to optimize AstraZeneca compounds

BioMerieux-Pierre Fabre (France)

Eli Lilly and Co.

Collaboration on eflucimibe; BioMerieux-Pierre will receive a signing fee, milestone payments and royalties on product sales; companies will jointly promote and market the product except for certain countries in which Lilly receives exclusive rights

Biomira Inc. (Canada; BIOM; TSE:BRA)

Merck KGaA

$150

Global collaboration agreement for 15 years for two vaccines, Theratope and BLP25; companies will jointly market them in the U.S.; Merck will have development and marketing rights in the rest of the world, except Israel and the Palestinian Autonomy Area

Cell Pathways Inc. (CLPA)

Bristol-Myers Squibb Co.

Agreement to support a Phase I/II trial studying the combination of Aptosyn and Taxol plus Paraplatin as a first-line treatment for advanced non-small-cell lung cancer; companies will share the costs and data

Cephalon Inc. (CEPH)

Armstrong Laboratories de Mexico SACV (Mexico) and Sintong Chemical Industrial Co. Ltd. (Taiwan)

Agreement for the marketing and distribution rights of modafinil

Chiron Corp. (CHIR)

F. Hoffmann-La Roche Ltd. (Switzerland)

Licensing deal for HIV-1 and hepatitis C virus intellectual property for nucleic acid testing to screen blood, plasma and blood products intended for transfusion; Roche gains a license to manufacture and sell the tests worldwide

Digene Corp. (DIGE)

Abbott Laboratories Inc.

Terminated marketing and distribution agreement for Digene's human papillomavirus DNA tests and accessories

Dyax Corp. (DYAX)

Wyeth-Genetics Institute (unit of American Home Products Corp.)

Commercial license agreement for a unique, chemically sizeable ligand, which has a specificity for purification of ReFacto, Wyeth-Genetic's Factor VIII product

Entelos Inc.

Organon (the Netherlands)

Research and development collaboration in rheumatoid arthritis

Genmab A/S (Denmark; CSE:GEN; Neuer Markt:GE9D)

F. Hoffmann-La Roche Ltd. (Switzerland)

Collaboration for the creation and development of human antibody therapeutics; Roche gains access to Genmab's capabilities and Genmab will receive milestone and royalty payments on successful products; it also could receive rights to develop products based on disease targets identified by Roche

Genzyme Transgenics Corp. (GZTC)

Elan Corp. plc (Ireland)

Agreement with an Elan subsidiary to develop one of Elan's monoclonal antibodies as a potential treatment for an undisclosed disease; the antibody will be produced in goats that will express the protein in their milk

Graffinity Pharmaceutical Design GmbH (Germany)

Aventis Pharma AG (Germany)

Discovery alliance to use Graffinity's chemical microarray-based discovery platform for identification of lead structures for Aventis targets; financial details were not disclosed

Isis Pharmaceuticals Inc. (ISIP)

Merck & Co. Inc.

$50

Licensing deal for Isis' preclinical Type II diabetes drug candidate, ISIS 113715; Isis expects to receive about $10M in 2001 from the deal, which also includes up-front and preclinical reimbursement fees

Martek Biosciences Corp. (MATK)

The Torrey Mesa Research Institute (subsidiary of Syngenta; Switzerland)

Joint research and development project to find and characterize genes from microalgae, focusing primarily on the docosahexaenoic acid (DHA) pathway; involves cross-royalty arrangements, with Martek having exclusive, worldwide commercialization rights to use genes in microbial production of DHA and the Torrey Institute having rights to use genes in agricultural crop species; financial details were not disclosed

Micromet AG (Germany)

Byk Gulden GmbH (Germany)

Agreement to find drug targets associated with lung cancer; Micromet will use its technologies and select pathogenic cells from patients' tissue samples; then, it will check the cells' gene expression profiles and genomic aberrations

Miravant Medical Technologies Inc. (MRVT)

Pharmacia Corp.

$20

Agreement for up to $20M in funding that includes sale of Miravant's PhotoPoint drug SnET2 in Phase III trials for treatment of wet age-related macular degeneration

Pharmacyclics Inc. (PCYC)

Nycomed Amersham plc (UK)

$2.75

Agreement to return worldwide rights to Lutrin to Pharmacyclics; the company now has worldwide rights to Europe, Asia, South and Central America; Amersham will pay Pharmacyclics a one-time $2.75M fee to cover future research and development obligations

ProdiGene Inc.

Eli Lilly and Co.

Research agreement to evaluate the feasibility of using ProdiGene's maize transgenic production system to develop and produce an enzyme that could be used as an intermediate in manufacturing processes

Proteome Systems Inc. (Australia)

Sigma-Aldrich Corp.

Agreement granting Sigma-Aldrich manufacturing and distribution rights to products, such as ProteoPrep, developed in collaboration

StemCell Technologies Inc. (Canada)

Applied Imaging Corp.

Exclusive supply agreement for reagents using StemCell's nonmagnetic cell separation technology; StemCell will supply RosetteSep tumor enrichment products and technology and Applied Imaging can market and sell the products

The Medicines Co. (MDCO)

Medison Pharma Ltd. (Israel)

Exclusive marketing and distribution agreement for the registration, distribution and promotion of Angiomax in Israel

Theratechnologies Inc. (Canada; TSE:TH)

Alza Corp.

Agreement to develop a product incorporating Alza's Macroflux skin interface technology and Theratechnologies' ThGRF (TH 9507)

April - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

3-Dimensional Pharmaceuticals Inc. (DDDP)

Boehringer Ingelheim Pharmaceuticals Inc.

Companies extended their drug discovery collaboration, begun in December 1999, for new compounds against asthma and allergic diseases; 3DP will receive an additional up-front payment, research and development funding, and is eligible for milestone payments and royalties on each compound selected

Alkermes Inc. (ALKS)

Eli Lilly and Co.

Collaboration to develop an inhaled formulation of insulin using Alkermes' AIR pulmonary drug delivery system; Alkermes will receive funding for development, milestone payments and royalties; Lilly will receive exclusive worldwide rights to resulting products

Crucell NV (the Netherlands; CRXL)

Merck & Co. Inc.

Agreement to apply Crucell's PER.C6 technology to Merck's HIV-1 vaccine program; includes an up-front fee, ongoing fees and royalty and milestone payments for Crucell; Merck has an option to extend the exclusivity to cover three unnamed disease areas

Cyclacel Ltd. (UK)

AstraZeneca plc (UK)

8 (US$11.49)

Agreement is for a research-stage cancer program in small-molecule inhibitors of the cell cycle; Cyclacel will receive up-front fees and milestones, as well as royalties, under terms of the two-year agreement

Epimmune Inc. (EPMN)

Neuralab Ltd. (subsidiary of Elan Corp. plc; Ireland)

License and option agreement to allow further evaluation of Epimmune's PADRE technology for use in immunological treatments for Alzheimer's disease

Gene Logic Inc. (GLGC)

Sankyo Co. Ltd. (Japan)

Subscription agreement to the BioExpress Module and the ToxExpress Module of Gene Logic's GeneExpress Suite of databases to be used in Sankyo's drug discovery and development programs

Incyte Genomics Inc. (INCY)

Eisai Co. Ltd. (Japan)

Multiyear subscription deal for Incyte's LifeSeq Gold database and the ZooSeq animal model database

Inex Pharmaceuticals Corp. (Canada; TSE:IEX)

Elan Pharmaceuticals plc (Ireland)

C$60 (US$39)

Joint venture to develop and commercialize Inex's lead anticancer product, Onco TCS; the deal includes a C$7.5M up-front purchase of Inex stock and a profit-sharing arrangement

InfiMed Therapeutics Inc.

Nikken Chemicals Co. Ltd. (Japan)

Collaboration on the development of InfiMed's Infitropin CR to treat growth failure in children

InSite Vision Inc. (AMEX:ISV)

SSP Co. Ltd. (Japan)

Licensing agreement for ophthalmic indications of the fluoroquinolone compounds SS732 and SS734; InSite will develop SS734/DuraSite in the U.S. and Europe, and SSP will develop it for Japan

Introgen Therapeutics Inc. (INGN)

Aventis Pharma (division of Aventis SA; Germany)

$20

Agreement giving Introgen manufacturing and commercial rights to the p53 gene therapy product, INGN 201, in development for head and neck cancer, as well as a $20M equity investment from Aventis and a 5% stake in Aventis' spin-off of its Gencell therapy division

Lynx Therapeutics Inc. (LYNX)

AstraZeneca plc (UK)

Collaborative research agreement that aims to identify genes that are differentially expressed between different human tissues; Lynx will use Megasort technology and will receive milestone payments

MGI Pharma Inc. (MOGN)

Helsinn Healthcare SA (Switzerland)

$11

Agreement granting MGI exclusive North American license and distribution rights to palonosetron; the deal includes $11M in up-front payments by MGI

m-phasys GmbH (Germany)

GlaxoSmithKline plc (UK)

Research agreement to target the in vitro functionality of a single, undisclosed G protein-coupled receptor

Neurogenetics Inc.

Eisai Co. Ltd. (Japan)

Agreement giving Eisai first negotiation rights to collaborate on selected Alzheimer's disease programs

Progenics Pharmaceuticals Inc. (PGNX)

F. Hoffmann-La Roche Ltd. (Switzerland)

Research collaboration renewed; agreement is focused on the discovery and development of novel HIV therapeutics

ProMetic Life Sciences Inc. (Canada; TSE:PLS)

Merck KGaA

Alliance to jointly market their knowledge of the monoclonal antibody purification field; ProMetic will provide its Mimetic Ligand technology and Merck will provide ion-exchange polymeric bioprocessing media products, as well as its sales force and distribution network

Titan Pharmaceuticals Inc. (AMEX:TTP)

Novartis Pharma AG (Switzerland)

Agreement for the development and commercialization in Japan of Zomaril; Titan receives license fees and milestone payments, as well as royalties.

Valentis Inc. (VLTS)

GlaxoSmithKline plc (UK)

Valentis granted GlaxoSmithKline a nonexclusive license to its GeneSwitch technology for gene regulation

Vysis Inc. (VYSI)

Abbott Laboratories Inc.

Agreement giving Abbott exclusive distribution rights in North America and Europe for the PathVysion HER-2 assay and the UroVysion assay

X-Ceptor Therapeutics Inc.

Sankyo Co. Ltd. (Japan)

$45

Three-year research and development agreement for selective modulators of the liver X receptor; the $45M agreement includes more than $20M in up-front funding and research support

March - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Acambis plc (UK)

Swiss Serum and Vaccine Institute Berne (Switzerland)

Alliance grants the institute an exclusive sales and marketing license for an oral typhoid vaccine in all territories outside the U.S. and Canada; the institute will fund all development and supply of clinical materials and it will manufacture the vaccine and supply it to Acambis; Acambis gains exclusive sales and marketing rights in the U.S. and Canada to sell an oral cholera vaccine, Orochol Berna, in combination with Acambis' oral typhoid vaccine

Amrad Corp. Ltd. (Australia)

GlaxoSmithKline plc (UK)

A$50 (US$25.44)

Collaboration and license agreement focusing on two components of Amrad's suppressors of cytokine signaling platform technology, which has potential to treat cancer and infectious diseases; Amrad will receive research and development funding for two years and up to US$25.44M in milestone payments and royalties

Applied Biosystems Group (NYSE:PEB; unit of Applera Corp.)

Pantheco A/S (Denmark)

Nonexclusive license agreement to manufacture peptide nucleic acids for research and development purposes; Applied Biosystems acquired a small minority stake in Pantheco

Arena Pharmaceuticals Inc. (ARNA)

Taisho Pharmaceutical Co. Ltd. (Japan)

Receptor-discovery research collaboration to identify a G protein-coupled receptor and to apply Arena's CART technology to the receptor; Taisho will make an up-front payment

Biotech Holdings Ltd. (Canada; OTC BB:BIOHF)

Bilim Pharmaceuticals Inc. (Turkey)

Agreement for the distribution of DIAB II in Turkey

Celltech Group plc (UK; LSE:CCH; NYSE:CLL)

Pharmacia Corp.

$280

Co-development and marketing deal for the humanized antibody fragment CDP 870; Celltech will receive a share of profits and royalties; the deal includes up-front payments of $50M and another $230M in milestones

Cogent Neuroscience Inc.

Elan Corp. plc (Ireland)

Agreement to form a joint development venture to discover and develop therapeutic gene targets for a group of intractable brain disorders called polyglutamine disorders; Elan will provide research support and will make an undisclosed equity investment in Cogent

Cytomedix Inc. (OTC BB:CYDX)

DePuy AcroMed Inc. (Subsidiary of DuPuy Inc.)

Licensing agreement giving Cytomedix access to DuPuy patents in the fields of spinal and orthopedic surgeries and neurosurgery

DeCode genetics Inc. (DCGN)

Roche Holding AG

$50

Five-year collaboration to develop DNA-based diagnostic systems and products, which analysts say could be worth more than $50M in research and development funding and milestone payments

De Novo Pharmaceuticals Ltd. (UK)

N.V. Organon (the Netherlands)

Drug design collaboration; Organon paid a technology access fee and will provide research funding for one year and pay milestone payments on discovery and development achievements; De Novo will offer its computer algorithms to provide Organon with small-molecule leads in an undisclosed research area

D-Pharm Ltd. (Israel)

Eli Lilly and Co.

Central nervous system research collaboration; Lilly will make an equity investment in D-Pharm and will have an option to exclusively license resulting compounds for worldwide development and commercialization; D-Pharm also will receive license fees and development milestones, as well as royalties on worldwide sales

Durect Corp. (DRRX)

Mallinckrodt Inc.

Supply agreement for Durect's clinical and commercial requirements for sufentanil

GeneData AG (Switzerland)

Novartis Pharma AG (Switzerland)

Multiyear collaboration to characterize the genomes of pathogenic bacteria, identify antibacterial targets and aid in selection of compounds for the development of new antimicrobial drugs

Genencor International Inc. (GCOR)

DuPont Pharmaceuticals Inc.

Agreement expanding their multiyear research and development collaboration focused on metabolic pathway engineering; Genencor will receive research and development funding, potential milestone payments and royalties on product sales

Icagen Inc.

Abbott Laboratories Inc.

Extended discovery and development collaboration for two years, expanded to include the development of small-molecule drugs that target ion channels to treat urological disorders, benign prostatic hypertrophy and sexual dysfunction

ImmuCell Corp. (ICCC)

Novatreat Ltd. (Finland)

$0.1

License and supply agreement covering certain nutritional and risk reduction rights for functional food applications of ImmuCell's DiffGAM technology outside North America

Innogenetics NV (Belgium)

Bayer Corp.

EUR20.4 (US$18.4)

Agreements in the field of in vitro nucleic acid-based viral diagnostics; Bayer acquired the exclusive worldwide rights for the sale and marketing of Innogenetics' LiPA HIV and LiPA HCV products; Bayer will make a payment of EUR10.4M (US$9.4M), a future milestone payment and research and development funding for the next five years; Bayer also will make a EUR10M equity investment in Innogenetics

InterMune Pharmaceuticals Inc. (ITMN)

Boehringer Ingelheim GmbH (Germany)

Strategic alliance for certain development and commercialization rights to interferon gamma-1b in all territories other than the U.S., Canada and Japan; InterMune will receive a 20% royalty rate, under particular conditions, on sales of the product

Isis Pharmaceuticals Inc. (ISIP)

Merck & Co. Inc.

One-year extension to their research collaboration to discover drug candidates to treat patients infected with the hepatitis C virus

Ligand Pharmaceuticals Inc. (LGND)

Elan Corp. plc (Ireland)

$10

Exclusive European territorial distribution agreement focusing on five Ligand oncology products: Ontak, Targretin capsules, Targretin gel, Panretin capsules and Panretin gel; deal includes an up-front payment and milestone payments

LION Bioscience AG (Germany; LEON)

Intervet International GmbH (The Netherlands)

Extended bioinformatics collaboration including licenses for the data integration technology SRS and the automated gene and genome annotation system bioSCOUT, as well as new licenses for genomeSCOUT gene comparison software and SRS everEST

Lorus Therapeutics Inc. (Canada; LORFF; TSE:LOR)

Dalton Chemical Laboratories Inc. (Canada)

Manufacturing agreement for Virulizin, which will enter Phase III later this year

Lynx Therapeutics Inc. (LYNX)

AstraZeneca plc (UK)

Collaboration applying Lynx's Megatype technology to discover single nucleotide polymorphisms associated with asthma; Lynx will receive an up-front payment, as well as milestone payments

MDS Proteomics Inc. (Canada; subsidiary of MDS Inc.; NYSE:MDZ; TSE:MDS)

Partners Healthcare Inc.

Clinical research alliance to study protein-to-protein pathways

Medarex Inc. (MEDX)

Schering-Plough Corp.

Research alliance to develop fully human antibodies against multiple disease targets identified by Schering-Plough; Medarex will receive license fees, milestone payments and royalties

Message Pharmaceuticals Inc.

Aventis Pharmaceuticals Inc.

Collaboration to investigate post-transcriptional regulatory mechanisms associated with a number of genes of interest to Aventis

Metabasis Therapeutics Inc.

Sankyo Co. Ltd. (Japan)

Extended joint research collaboration, initiated in 1997, to develop oral drugs to treat diabetes mellitus, through May 2002; Sankyo will extend its research funding

Millennium Pharmaceuticals Inc. (MLNM)

Abbott Laboratories Inc.

$250

Five-year agreement is focused on obesity and diabetes; Abbott will buy $50M in Millennium stock when the deal closes, and $200M more over the next two years; companies will split commercialization efforts in the U.S., and Abbott is responsible for the rest of the world; Millennium gets the right to co-promote in major European markets and worldwide profits will be shared

Morphochem AG (Germany)

Aventis Pharma AG (Germany)

Research and development collaboration to use Morphochem's high-throughput chemistry to develop compounds that interact with an undisclosed diabetes target; Aventis will pay a success fee and will fund the work, as well as pay milestones and royalties

Morphochem AG (Germany)

Sosei Ltd. (Japan)

Morphochem will optimize a potential cancer drug with Sosei using its capabilities in multicomponent reaction chemistry; the companies will share results from the collaboration equally

NaPro BioTherapeutics Inc. (NPRO)

F.H. Faulding & Co. Ltd. (Australia)

$7.5

Marketing and distribution agreement covering NaPro paclitaxel in Europe; Faulding will pay an up-front licensing fee of $7.5M and the firms will share equally the net sales in the new territories

NeoGene Technologies (Subsidiary of NeoTherapeutics Inc.; NEOT)

Pfizer Inc.

Agreement focused on NeoGene's milieu, G protein-coupled receptors; includes an initial payment and milestone payments on potential products; Pfizer is partnering with NeoGene on one orphan GPCR

NPS Pharmaceuticals Inc. (NPSP)

AstraZeneca plc (UK)

Five-year collaboration in which NPS is licensing its technology related to mGLuR, and molecules that act at those receptors; AstraZeneca will match NPS's funding levels and offer NPS options either to co-promote products in North America or get royalties

Organogenesis Inc. (AMEX:ORG)

Royce Medical Co.

Collaboration for certain uses of Organogenesis' engineered collagen technology

Pharmacopeia Inc. (PCOP)

Mitsubishi-Tokyo Pharmaceuticals (Japan)

Collaboration agreement under which Pharmacopeia will use its assay development knowledge, compound sample collection and ultra-high-throughput screening technology to identify compounds against a Mitsubishi target; Pharmacopeia will receive fees and milestone payments, as well as royalties

Pharmagene plc (UK; LSE:PGN)

Bayer Corp. (Germany)

Drug discovery agreement in which Pharmagene will identify gene expression patterns across a matrix of diseased and nondiseased human tissue samples, constructed to depict nine cancer types of interest to Bayer in order to characterize therapeutic proteins and antibody targets

Pharmagene plc (UK; LSE:PGN)

Taisho Pharmaceutical Ltd. (Japan)

Phase ZERO agreement calling for Pharmagene to use human hepatocytes to investigate gene expression profiling, and to use human tissue to carry out pharmacological profiling on Taisho compounds

Pharsight Corp.

iBiomatics LLC

Collaboration in which the companies will market an integration of Pharsight's Computer-Assisted Trial Design methodology, the Pharsight Trial Simulator and iBiomatics' web-based platform for biomedical informatics

Procyon BioPharma Inc. (Canada; TSE:PBP)

International Medical Innovations Inc. (Canada)

Licensing agreement giving IMI the worldwide exclusive license to develop, market and distribute its colorectal cancer screening technology, Colopath; Procyon will receive an up-front payment, as well as milestones and royalties

RiboTargets Ltd.

Johnson & Johnson

Two-year agreement is for the development of antibiotics around two novel targets on the bacterial ribosome

Vernalis Group plc (UK)

Eli Lilly and Co.

The companies extended their license agreement for VML 670 to develop the compound as a treatment for sexual dysfunction, in addition to delayed emesis in patients receiving cancer chemotherapy

Vivus Inc. (VVUS)

Tanabe Seiyaku Co. Ltd. (Japan)

Vivus licensed worldwide rights to develop and commercialize Tanabe's phosphodiesterase type 5 inhibitor compound TA-1790 for male and female sexual dysfunction; rights do not include Japan, China and certain Pacific Rim countries; Tanabe received an undisclosed up-front payment and will receive milestone payments and royalties

Xanthon Inc.

CMED/RELA (A division of Colorado MEDtech Inc.)

Multiyear agreement to manufacture production quantities of the Xanthon Xpression Analysis Instrument

February - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

AEterna Laboratories Inc. (Canada; AELA)

Grupo Ferrer Internacional SA (Spain) and Medac GmbH (Germany)

C$35 (US$23)

Agreements for commercialization and distribution rights to Neovastat in Europe; agreements include double-digit royalties, milestone payments and research-expense sharing for new indications

AlphaRx Inc. (OTC BB:AHRX)

Taiwan PanBiotic Laboratories Co. Ltd. (Taiwan)

Letter of intent to enter into a strategic alliance to commercialize AlphaRx drug discovery products - nutraceuticals - in Taiwan

Amgen Inc. (AMGN)

Megapharm Ltd. (Israel)

Agreement grants Megapharm marketing and distribution rights for Aranesp in Israel

Antex Biologics Inc. (AMEX:ANX)

O.E.M. Concepts Inc.

Agreement for the development and manufacture of antibodies for commercial use in the detection of food-borne and other enteric pathogens; Antex will receive royalties on sales

BioStratum Inc.

Kowa Co. (Japan)

$25

License agreement granting exclusive rights in Japan, China, Korea and Taiwan to Kowa for the development, manufacturing and marketing of BioStratum's Pyridorin to treat diabetic kidney disease

Cerep SA (France)

F. Hoffmann-La Roche Ltd. (Switzerland)

Three-year drug discovery agreement calling for Cerep to use its technology in high-throughput screening, pharmacological and pharmaceutical profiling, and classic pharmacology

Chiron Corp. (CHIR)

R.W. Johnson Pharmaceutical Research Institute

Nonexclusive license for the research, development and commercialization of small-molecule therapeutics against a specific hepatitis C virus drug target contained in HCV genomes

EpiGenesis Pharmaceuticals Inc.

Taisho Pharmaceuticals Co. Ltd. (Japan)

$100

Agreement for Asian development and license rights for EPI-2010, which calls for co-ownership of North American marketing, distribution and commercialization rights

GeneData AG (Switzerland)

Novartis Pharma AG (Switzerland)

Multiyear license agreement for the microarray data analysis system, GeneData Expressionist

Genome Therapeutics Corp. (GENE)

Wyeth-Lederle Vaccines (Unit of Wyeth-Ayerst Research, a division of American Home Products Corp.)

Contract to identify the complete DNA map of a pathogenic organism

HTS Biosystems Inc.

Mitsubishi Chemical Corp. (Japan)

License, purchase and distribution agreement for HTS's bioanalysis system in Japan

Hybrigenics SA (France)

Group de Recherche Servier (France)

Three-year drug target discovery collaboration and license agreement for anticancer drugs; Servier will supply proteins and Hybrigenics will map protein-protein interactions in specific cellular pathways; Servier will provide research funding, as well as up-front cash and milestone payments, as well as royalties on potential sales

Illumina Inc. (ILMN)

Chevron Research and Technology Co.

Agreement to determine how BeadArray technology could be developed and applied to hydrocarbon processing operations

Immusol Inc.

Chugai Pharmaceutical Co. Ltd. (Japan)

Functional genomics collaboration for drug discovery, using Immusol's gene inactivation technology; agreement will focus on drug target genes relating to cancer metastasis

InKine Pharmaceutical Co. Inc. (INKP)

Procter & Gamble Pharmaceuticals

An 18-month, co-promotion agreement under which the P&G gastrointestinal sales force will promote Visicol, approved for bowel cleansing, to gastroenterologists and colorectal surgeons

InKine Pharmaceutical Co. Inc. (INKP)

Unnamed pharmaceutical company

Manufacturing agreement for IBStat

LifeSpan BioSciences Inc.

Bristol-Myers Squibb Co.

Subscription agreement for the first database on information on the expression and localization of G protein-coupled receptors

LumiCyte Inc.

Kratos Analytical Ltd. (UK)

Multimillion-dollar agreement under which Kratos will supply mass spectrometers to support LumiCyte's protein biochip data aggregation facilities worldwide

Luminex Corp. (LMNX)

Dynacare Inc. (DNCR)

Companies entered a strategic partnership to develop and commercialize clinical laboratory assays based on Luminex's LabMAP technology

Maxygen Inc. (MAXY)

ALK-Abello A/S (the Netherlands)

$80

Three-year research and development deal for recombinant therapeutics for allergy treatment; deal includes license fees, technology access fees, research and development funding, potential milestones and royalties

MediChem Life Sciences Inc.

AstraZeneca plc (UK)

Renewed and expanded collaboration to provide AstraZeneca with synthetic libraries and novel method development discoveries to advance drug discovery programs

MGI Pharma Inc. (MOGN)

Helsinn Healthcare SA (Switzerland)

Companies signed a letter of intent to enter a North American license and distribution agreement for Helsinn's palonosetron to prevent chemotherapy-induced nausea and vomiting

NewBiotics Inc.

Elan Corp. plc (Ireland)

Joint venture to develop a product, NB1011, to treat colorectal cancer in patients who do not respond well to standard chemotherapy; agreement includes an investment in NewBiotics, as well as up-front and milestone payments

Orchid BioSciences Inc. (ORCH)

AstraZeneca plc (UK)

Multiyear genotyping agreement in which Orchid will conduct studies using single nucleotide polymorphisms; gives AstraZeneca access to Orchid's SNP databases and the use of SNP panels

Organogenesis Inc. (AMEX:ORG)

Novartis AG (Switzerland)

$20

Amended agreement calling for Organogenesis to sell Novartis up to $20M in equity over the next three years; it gives Organogenesis higher payments from Novartis for the skin substitute Apligraf

Pharmagene plc (UK; LSE:PGN)

Bayer plc (Germany)

Drug discovery agreement using Pharmagene's knowledge in human tissue to generate a dataset to aid the validation of potential drug targets identified by Bayer

PharmaSeq Inc.

Mitsui and Co. (Japan)

Strategic partnership under which PharmaSeq receives a multimillion-dollar equity investment from Mitsui; PharmaSeq is developing laser light-powered microchips for applications in gene diagnostics, drug discovery and proteomics

Pharming Group NV (the Netherlands; PHAR)

AM-Pharma (the Netherlands)

Pharming licensed its small antibacterial peptides technology to AM-Pharma for an equity stake in AM-Pharma

Physiome Sciences Inc.

Janssen Pharmaceutica NV (unit of Johnson & Johnson)

Multiyear licensing and development agreement grants J&J rights to test candidate drugs on computers using Physiome's CardioPrism software and physiological information databases

PPL Therapeutics plc (Scotland)

Nihon Nosan Kogyo KK (Japan)

Exclusive commercialization agreement for the sales and marketing of PPL's transgenic production technology platform in Japan

Sequenom Inc. (SQNM)

Genomics Institute of the Novartis Research Foundation

Collaboration to validate and map single nucleotide polymorphisms in the mouse genome and apply the information to identify candidate genes associated with human disease

SkyePharma plc (UK; LSE:SKP; SKYE)

Kowa Ltd. (Japan)

SkyePharma signed a contract for the scale-up and manufacturing of Phase III clinical batches of Kowa's new lipid-lowering agent, NK-104

Telik Inc. (TELK)

Sanwa Kagaku Kenkyusho Co. Ltd. (Japan)

$2.25

Extended research collaboration to use TRAP chemogenomics drug discover technology to identify and optimize compounds for targets in inflammatory disorders and diabetes; Sanwa takes exclusive Asian commercialization rights and Telik retains U.S. rights

Teva Pharmaceutical Industries Ltd. (Israel; TEVA)

H. Lundbeck AS (Denmark)

Extended strategic collaboration to include the oral formulation of Copaxone in clinical studies for multiple sclerosis

ViroPharma Inc. (VPHM)

Sanofi-Synthelabo (France)

Revised 1995 licensing agreement for pleconaril, reducing royalty rates for U.S. and Canadian sales and eliminating milestone payment requirements for ViroPharma, following the selection of a marketing partner

January - 2001

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Abgenix Inc. (ABGX)

Lonza Biologics (UK)

Manufacturing agreement for five years of a cell culture production suite at Lonza's facility in Slough, England

Abgenix Inc. (ABGX)

Pfizer Inc.

Expanded agreement adds 10 antigen targets to the 8-year human antibody collaboration; Abgenix receives an undisclosed fee to extend the $30M agreement begun in December 1997

Adprotech Ltd. (UK)

Elan Corp. plc (Ireland)

Research agreement to evaluate Adprotech's Immudaptin adjuvant technology for use in an immunotherapeutic for Alzheimer's disease

Amgen Inc. (AMGN)

Genesis Pharma SA (Greece)

Agreement grants Genesis certain exclusive rights to distribute, market and sell Aranesp in Greece and Cyprus

Arena Pharmaceuticals Inc. (ARNA)

Taisho Pharmaceutical Ltd.

Expanded agreement in which Arena will license rights to its obesity target, the GPCR18F receptor, in return for an up-front payment, milestone payments and full-time equivalent payments and royalties

ArQule Inc. (ARQL)

Solvay Pharmaceuticals Inc.

Extended 1995 agreement through 2003 to provide Solvay with access to ArQule's Compass Array libraries and continued use of ArQule's Directed Assay program; ArQule will receive delivery fees, research payments, milestone payments and royalties

Artemis Pharmaceuticals GmbH (Germany)

DuPont Pharmaceuticals Co.

Nonexclusive license agreement for functional genomics applications of Cre-lox technology

Athersys Inc.

Bristol-Myers Squibb Co.

Agreement for access to RAGE-VT technology for production of human cell lines expressing six validated drug targets; Athersys gets a licensing fee for each cell line, as well as milestone payments and royalty payments

Atrix Laboratories Inc. (ATRX)

Sanofi-Synthelabo (France)

$60

Exclusive North American marketing agreement for Leuprogel products; agreement includes a license fee, research and development support and payments for milestones and royalties, as well as a $15M equity investment in Atrix by Sanofi

Aurora Biosciences Corp. (ABSC)

GlaxoSmithKline plc (UK)

Second multiyear ion channel drug discovery technology agreement in which Aurora will provide access to its technology for drug discovery and target validation

Aurora Biosciences Corp. (ABSC)

R.W. Johnson Pharmaceutical Research Institute

Expansion to May 2000 agreement for Aurora's ion channel technology platform; Aurora will provide additional instrumentation, voltage sensing probes and ongoing scientific and technical support

Bavarian Nordic Research Institute AS (Denmark)

Vaccine Solutions Pty. Ltd. (Australia)

License agreement for the right to sublicense, develop, produce, manufacture and market HIV vaccines incorporating Polytope technology; includes up-front, milestone and royalty payments to Vaccine Solutions

Biobase GmbH (Germany)

Aventis Pharma AG (Germany) and NV Organon (the Netherlands)

Subscriptions agreement to the Transfac Professional database

Biophage Inc.

Nymox Pharmaceutical Corp.

Collaboration on novel antimicrobial treatments and applications development

BioTrove Inc.

Pfizer Inc.

Collaboration to develop BioTrove's ultra-high-throughput screening technology for use in Pfizer's research facilities

Boston Life Sciences Inc. (BLSI)

Marathon Biopharmaceuticals Inc.

Supply agreement calling for Marathon to manufacture GMP Troponin I for clinical testing

Cambridge Antibody Technology (UK; LSE:CAT)

Elan Corp. plc (Ireland)

Strategic partnership to develop neurological disorder therapeutics; Elan will provide targets and CAT will use its antibody phage display technology and high-throughput screening capabilities in the four-year agreement, which calls for equal development cost and profit sharing

Celgene Corp. (CELG)

Novartis Pharma AG (Switzerland)

Research and development partnership for selective estrogen receptor modulator compounds for osteoporosis; Novartis will make an up-front payment to Celgene, as well as milestone and royalty payments, in return for worldwide development and commercial rights

Celltech Group plc (NYSE:CLL)

Johnson & Johnson

Research and development agreement for orally active cancer treatment compounds; J&J receives worldwide rights to the compounds and will be responsible for all costs and pay up-front, milestone and royalty payments

CeNeS Pharmaceuticals plc (UK; LSE:CEN)

Amarin Corp. plc (UK)

CeNeS licensed exclusive North American rights for Moraxen to treat severe pain; CeNeS will manufacture Moraxen for an up-front cash payment and royalties on future sales

Cephalon Inc. (CEPH)

The R.W. Johnson Pharmaceutical Research Institute

Access agreement for Cephalon's selective kinases inhibitors technology; Cephalon will receive up-front and milestone payments, as well as potential royalties

Cerus Corp. (CERS)

Pharmaceutical Division of Kirin Brewery Company Ltd. (Japan)

$12

Collaboration to develop stem cell transplantation products directed toward hematologic malignancies based on Cerus' Helinx technology; companies will jointly develop the products and Cerus will receive an initial license fee of $1M, plus up to $11M in milestone payments

Cetek Corp.

The R.W. Johnson Pharmaceutical Research Institute (PRI) (unit of Johnson & Johnson)

Research collaboration to develop capillary electrophoresis assays for PRI targets and screening against compound libraries from PRI

Chiron Corp. (CHIR)

Organon Teknika BV (the Netherlands; unit of Akzo Nobel AV)

Worldwide, semiexclusive license agreement for Chiron's patents of HIV in assays claiming the detection of nucleic acid sequences for use in clinical diagnostics

CollaGenX Pharmaceuticals Inc.

PharmaMed Inc.

Exclusive Middle East export marketing agreement for Periostat that includes a fee contingent on sales for PharmaMed

Corixa Corp. (CRXA)

CoPharma Inc.

License, development and commercialization agreement for Corixa's preclinical cardioprotectant, RC.522

Corixa Corp. (CRXA)

NV Organon (unit of Akzo Nobel; the Netherlands)

Amended agreement to include continued development of the recombinant form of Corixa's AnergiX.RA complex to treat rheumatoid arthritis

Cortex Pharmaceuticals Inc. (OTC BB:CORX)

NV Organon (unit of Akzo Nobel; the Netherlands)

Exercised option agreement to develop and commercialize Ampakines for depression; agreement includes research and development funding, as well as milestone and royalty payments

CuraGen Corp. (CRGN)

Bayer Corp. (Germany)

$124

Two agreements; one to discover, develop and jointly commercialize small-molecule drugs to treat obesity and adult onset diabetes, in which both companies will jointly fund up to $1.34B over a 15-year period; the other agreement is for CuraGen to apply its technologies to evaluate Bayer's early stage drug candidates and preclinical compounds across all disease areas, which is valued at $124M and includes an $85M equity investment in CuraGen by Bayer

Cypress Bioscience Inc.

Fresenius AG (Germany)

Restructured Prosorba column sales, marketing clinical efforts worldwide agreement in which Cypress will receive an up-front payment of $8M

Cytoclonal Pharmaceutics Inc. (CYPH)

Bristol-Myers Squibb Co.

Extended agreement for research and development of new technology based on microbial fermentation for production of novel taxane therapeutics and paclitaxel; Bristol-Myers will make a $2M payment to Cytoclonal for research support

Cytomedix Inc. (OTC BB:CYDX)

Curative Health Services Inc.

$3.8

Cytomedix acquired worldwide manufacturing, sales and distribution rights to Procuren solution for $3.8M

DepoMed Inc. (AMEX:DMI)

Collaboration with an unnamed pharmaceutical company to develop an improved, controlled-release product, using one of DepoMed's delivery systems

Discovery Partners International Inc. (DPII)

Abbott Laboratories Inc.

Exclusive licensing agreement for Abbott's MicroArrayed Compound Screening technology; Abbott will receive royalties on net sales

Diversa Corp. (DVSA)

The Dow Chemical Co.

Licensing agreement for several enzymes for early stage testing; Diversa receives license fees and is entitled to royalties

GeneFormatics Inc.

Takara Shuzo Co. Ltd. (Japan)

Commercialization agreement for the protein structure/function determination technology in Asia

Gene Logic Inc. (GLGC) and Affymetrix Inc. (AFFX)

Pfizer Inc.

Research collaboration to co-design and develop a custom GeneChip technology for mechanistic toxicology

GPC Biotech AG (Germany; Frankfurt:GPC)

Boehringer Ingelheim International GmbH (Germany)

$30

Alliance to use GPC's technology platform to identify novel targets and their molecular pathways associated with human papilloma virus; includes an undisclosed up-front license fee, research funding and development milestones, as well as royalties

GPC Biotech AG (Germany; FSE:GPC)

Byk Gulden (pharmaceutical unit of Altana AG; Germany)

$100

Five-year target identification and drug discovery alliance to identify tumor-specific targets that selectively cause apoptosis in cancer cells

Heska Corp. (HSKA)

Novartis Animal Health (subsidiary of Novartis AG; Switzerland)

Distribution agreement for exclusive rights for Heska's E-Screen Test in Europe

ImaRx Therapeutics Inc.

Elan Corp. plc (Ireland)

Agreement to form a research joint venture to develop and commercialize HydroPlex drug delivery technology for an oncology product; Elan has made an equity investment in ImaRx and provided a credit facility

Incyte Genomics Inc. (INCY)

Corning Inc.

Licensing agreement for rights to Incyte's gene sequenced databases and gene patent portfolio

InfiMed Therapeutics Inc.

Praecis Pharmaceuticals Inc.

InfiMed will apply its Improved Formulation Entity platform for sustained release of protein- and peptide-based drugs to an undisclosed Praecis peptide

Inflazyme Pharmaceuticals Ltd. (Canada)

Aventis Pharma AG (Germany)

Expanded collaboration for research and development of anti-inflammatories; expansion to include IPL550,260 and IPL512,602

InterMune Pharmaceuticals Inc. (ITMN)

Alza Corp.

InterMune is buying Alza's drug Amphotec for $9M plus undisclosed milestone payments

LifeSpan BioSciences Inc.

Merck & Co. Inc.

Access agreement for LifeSpan's database of G protein-coupled receptor expression and localization information

Matritech Inc.

Timm Medical Technologies Inc.

$23

Distribution agreement for Matritech's NMP22 test for bladder cancer; deal includes an initial equity investment by Timm in Matritech, marketing fees, milestone payments and increasing minimum test purchases

Maxia Pharmaceuticals Inc.

The R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical Inc.

Multiyear collaboration to discover and develop insulin sensitizers to treat Type II diabetes and related metabolic disorders; agreement includes an up-front payment, research and development funding, milestone payments, royalties and equity investments

Medarex Inc. (MEDX) and Biosite Diagnostics Inc. (BSTE)

Eli Lilly & Co.

Agreement to use Trans-Phage technology to generate high-affinity, fully human antibodies to genomics-derived targets; Lilly will provide targets for three years; Biosite will receive technology access fees, fees upon target delivery, annual maintenance fees and milestones and royalties; Medarex will receive license fees and milestones and royalties

Microcide Pharmaceuticals Inc. (MCDE)

The R.W. Johnson Pharmaceutical Research Institute and Ortho McNeil Pharmaceutical Inc.

Microcide will receive an up-front license fee and one year of funding, as well as milestone payments and royalties in the amended research and license agreement to cover preclinical research to develop orally active cephalosporin

Millennium Pharmaceuticals Inc. (MLNM)

F. Hoffmann-La Roche Ltd. (Switzerland)

Three-year agreement focused on development of rheumatoid arthritis diagnostics; Millennium will receive license fees, research funding, milestone and royalty payments

Neurogen Corp. (NRGN)

Pfizer Inc.

$2.9

Fifth extension of the research collaboration for gamma-aminobutryic acid, resulting in another $2.9M in funding for Neurogen

Onyx Pharmaceuticals Inc. (ONXX)

XOMA Ltd.

$35

Strategic process development and manufacturing agreement for CI-1042 (ONYX-015) as an anticancer agent

Orchid BioSciences Inc. (ORCH)

PerkinElmer Inc.

Exclusive licensing agreement for Orchid's SNP-IT technology for single nucleotide polymorphism scoring applications using fluorescence polarization and energy transfer readout methods

Oxford BioMedica plc

American Home Products Corp.

$24

Agreement to develop and commercialize a novel anticancer therapy using an Oxford BioMedica antibody

Peptech Ltd. (Australia)

Knoll AG (Germany; unit of BASF Pharma) and Centocor Inc. (unit of Johnson & Johnson)

US$31

Development agreement for two anti-TNF products that could mean up to US$31M a year for several years, in addition to up-front and milestone payments

Pharmacopeia Inc. (PCOP)

N.V. Organon (the Netherlands)

Expanded relationship to include a new medicinal chemistry services agreement to optimize hits to lead compounds for Organon; Pharmacopeia will develop synthetic strategies and rapidly synthesize milligram quantities of a number of chemical analogues around a lead compound identified by Organon

Qiagen Genomics Inc. (QGENF)

Daiichi Pure Chemicals Co. Ltd. (Japan)

Purchase agreement for a Masscode system and a nonexclusive license to use related technology in providing SNP genotyping services to clients in Japan

Rigel Pharmaceuticals Inc. (RIGL)

Pfizer Inc.

Extended asthma/allergy research collaboration for one year; Pfizer will provide additional research funding and milestone payments

Sequenom Inc. (SQNM)

GlaxoSmithKline

Collaboration to screen about 500 identified single nucleotide polymorphisms and about 900 DNA samples from Type II diabetes mellitus patients and controls provided by GlaxoSmithKline

Sequitur Inc.

Bristol-Myers Squibb Co.

Multiyear, multimillion-dollar agreement to provide Bristol-Myers access to functional genomics technology

SkyePharma plc (UK)

Meditech Research Ltd. (Australia)

Agreement to commercialize Solaraze in Australia, New Zealand, Malaysia and Singapore

Structural Bioinformatics Inc.

R.W. Johnson Pharmaceutical Research Institute (PRI)

Access agreement for SBI's X-ray crystallography program; the agreement covers several undisclosed targets

Syn X Pharma Inc. (Canada; CDNX:SYY)

Janssen Research Foundation

Research collaboration to test Syn X's human stroke markers in Janssen's animal models for stroke and traumatic brain injury; Janssen will make research payments and will purchase products from Syn X for research purposes

Syrrx Inc.

Genomics Institute of Novartis Research Foundation

Five-year strategic alliance to codevelop automated systems to streamline and industrialize the protein structure determination process; Syrrx gains a worldwide exclusive license to structural proteomics tools and GNF will take a minority equity position in Syrrx

The FibroGen Group

Aventis Pasteur SA (France)

Collaboration to develop novel synthetic gelatins using FibroGen technology; agreement includes up-front payments, program funding, milestone payments, material supply revenues and royalty rights

Trega Biosciences Inc.

F. Hoffmann-La Roche Ltd. (Switzerland)

Licensing agreement for two modules of the iDEA Predictive ADME Simulation System for use in drug discovery

United Therapeutics Corp. (UTHR)

Orphan Australia Pty. Ltd.

Distribution agreement for UT-15 (Uniprost) in Australia and New Zealand

Versicor Inc. (VERS)

Pharmacia Corp.

Collaboration for discovery and development of oxazolidinones; original $30M collaboration dates to April 1999; Pharmacia will expand its financial support by 30%

Xenogen Corp.

AstraZeneca plc (UK)

Evaluation license agreement to allow access to Xenogen's technology in oncology

Xenogen Corp.

Pfizer Inc.

Research collaboration to develop new methods of identifying potential therapeutic drug targets with the use of transgenic mice; agreement terminates in December 2003, with the option to extend it for two more years

YM BioSciences Inc. (Canada)

SR Pharma plc (UK)

Agreement to collaborate to investigate the use of YMB's cancer antigen, IPS-21, in conjunction with SR Pharma's SRL172, a vaccine adjuvant

Zymark Corp.

Bayer Corp.'s Diagnostics Business Group

Collaboration to provide an automated platform for cell-based compound screening

Biotech/Big Pharma Collaborations - 2001

Today's news in brief

Today's news in brief

AACR 24: Freezing, of all things, is one way to heat cold tumors

Yuhan-Sorrento’s cancer-focused Immuneoncia targets Kosdaq IPO

Cerevel undersell? Bombshell Parkinson’s phase III with tavapadon

Upgrade your daily dose of biopharma and medtech news

Biotech/Big Pharma Collaborations - 2001